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Glossary of Terms
Term

Definition

Premature/Preterm
Neonate
Pasteurized Donor
Human Milk
Very Low
Birthweight
Necrotizing
Enterocolitis

Any newborn delivered prior to
completing 37 weeks of gestation
Donated human milk given to a milk bank
for feeding a neonate with medical need.
A neonate who weighs less than 1500
grams at time of birth
A potentially fatal intestinal disease that
primarily affects premature neonates.

Maternal Breast Milk

Human lactation produced by a female for
feeding her own child.
Human milk that has undergone
lactoengineering with an end result of
concentrated human milk, for addition to
either maternal breast milk or pasteurized
donor milk to increase caloric
concentration.
A nutritional strategy that utilizes bovinebased formula and/or bovine-based human
milk fortification to be provided when
mother’s milk is not available or
insufficient to meet the nutritional needs
of her child.
Enteral nutrition where all components are
derived from human milk.
Fortifier utilized to provide additional
calories to human milk. Comes in either
liquid or powder form. It is not human
milk nor is it concentrated human milk.

Pasteurized Human
Milk Fortification

Bovine Fortification
Nutritional Regimen

Exclusive Human
Milk Diet
Human Milk Fortifier

Abbreviation

vii

N/A
PDHM
VLBW
NEC

MBM
PHMF

BFNR

EHMD
HMF
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Creation of an Interdisciplinary Evidence-Based Advocacy Tool: Promoting Medicaid
Reimbursement for Pasteurized Donor Milk Provided to Very Low Birth Weight Neonates

Chapter One
Introduction
A strong body of scientific evidence establishes that human milk provides significant
benefit for newborns, particularly those born prematurely. However, an array of known and
predictable factors might prohibit a mother from providing sufficient milk volume to meet the
nutrient requirements of her premature neonate. When mother’s milk is unavailable or
inadequate, the provision of pasteurized donor human milk (PDHM) is a safe alternative to be
provided until mother’s milk is available or adequate. The World Health Organization (WHO),
the American Academy of Pediatrics (AAP), and the surgeon general all promote the provision
of PDHM to the very low birthweight neonate (less than 1500 grams; VLBW) when maternal
breast milk (MBM) is not available (World Health Organization, 2011; American Academy of
Pediatrics, 2012; U.S. Department of Health and Human Services, 2011). The AAP and the
National Association of Neonatal Nurses (NANN) recognize that current federal policies fail to
secure reimbursement for the provision of human milk to the VLBW neonate, and have
encouraged members to advocate for the inclusion of PDHM into their respective state Medicaid
programs (American Academy of Pediatrics, 2016; National Association of Neonatal Nurses,
2016). Advocates within six states (California, Kansas, New York, Missouri, Texas, and Utah)
and the District of Columbia have successfully lobbied state policy makers for PDHM
reimbursement (See Table 1).
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Statement of the Problem
In Georgia, no public policies ensure VLBW neonates have access to PDHM while
hospitalized. Presently VLBW neonates only have access to an exclusively human milk diet if
they are hospitalized at a medical facility that will absorb the cost of PDHM. Without
reimbursement policies, cost barriers may deny VLBW neonates an optimal diet.
Significance of the Problem
The potentially fatal disease necrotizing enterocolitis (NEC) has been linked to bovineprotein (formula) exposure since 1983 (Gross, 1983). Despite a robust body of literature
demonstrating the safety and efficacy of an exclusive human milk diet for the neonatal
population, full clinical utilization of human milk has not occurred. Cost has been reported as a
major limitation to the clinical utilization of PDHM when mother’s milk is not available (Parker
et al., 2013; AAP, 2016). Researchers have identified that safety-net hospitals (greater than 75%
of admissions rely upon Medicaid) were least likely to have access to PDHM (Parker et al.,
2013). Additionally, hospitals that operate in areas with a large portion of non-Hispanic black
residences were least likely to have access to PDHM (Boundy, Perrine, Nelson, & Hamner,
2017). Health care institutions and clinicians providing care to VLBW neonates should be able to
rely upon reimbursement policies reflective of costs incurred while providing evidence-based
care. Without such policies, cost barriers may deny VLBW neonates the most appropriate, and
potentially life-saving, nutrition.
In Georgia, 33% of all hospitals provide PDHM to their neonatal population (see Table
2). The biggest safety net hospital in the state, Grady Memorial Hospital, does not offer PDHM
(Miller, 2012).
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Nationwide the incidence of NEC in VLBW neonates fluctuates between 5% and 10%
(Neu & Walker, 2011; Thompson & Bizzarro, 2008). Considering that 54% of all neonates in the
state of Georgia are covered by Medicaid, securing reliable public funding for an exclusively
human milk diet would have a profound effect on NEC rates while saving money (Kaiser Family
Foundation, 2017). Additionally, development of a strategic advocacy plan, supported by clinical
and fiscal benefits, may be helpful in achieving reimbursement goals in other states.
Purpose and Goal
The purpose of this project is to promote Medicaid reimbursement policies for PDHM
provided to VLBW neonates in the state of Georgia. The proposed scholarship will contribute to
the ultimate goal: adoption of state-wide public policies which ensure every VLBW neonate in
Georgia has access to an exclusive human milk diet.
Aims
1. Describe current federal and Georgia state reimbursement policies concerning human
milk.
2. Utilize Coffman and Beer’s (2015) framework to describe an ideal advocacy strategy
that would lead to reimbursement for human milk by Georgia Medicaid.
3. In collaboration with an economist, work toward the development of a calculator that
will permit Medicaid directors to unitize state-specific data to demonstrate the cost
effectiveness of providing an exclusive human milk diet.
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Chapter Two
Background

Human milk decreases the incidence and severity of the potentially fatal gastrointestinal
disease, necrotizing enterocolitis (NEC; Cristofalo et al., 2013). NEC is the most common
acquired gastrointestinal (GI) complication in premature neonates (less than 37 weeks), and a
leading cause of death among very low birthweight neonates (less than 1500 grams; VLBW)
(Jacobs, Kamitsuka, Clark, Kelleher, & Spitzer, 2015). The treatment of NEC is estimated to cost
the U.S. health care system an annual minimum of $500 million (Neu & Walker, 2011).
The Vermont Oxford Network (VON) is an international collaborative database designed
to address quality improvement within neonatal intensive care units (NICU). Over 200 of the
hospitals that that provide care to VLBW neonates participate in VON (Frost, Modi, Jaksic, &
Caplan 2016). In 2015, VON reported a 5.1% (n = 59,752) mean network occurrence of NEC
(Vermont Oxford Database, 2016).
In 2015, there were 14,122 premature births, and 2,389 were VLBW neonates. The total
number of premature births in 2015 represents 10.8% of all births in Georgia, of which 1.8% of
the premature births were also VLBW (Georgia Department of Health; OASIS, 2016). While
current rates of NEC are unknown, the Georgia Department of Public Health (DPH) reported 134
fatal NEC cases between 2002 and 2006 (Georgia Department of Public Health, 2014).
Necrotizing Enterocolitis
NEC is a multifactorial disease resulting from intestinal immaturity, enteral nutrition,
endothelial inflammation, cytokine activation, and impaired mesenteric perfusion (Eaton, Rees,
& Hall, 2016). The exact cause is unknown. NEC has an array of presentations; the most fatal
occurs when the entire intestinal tract undergoes full-thickness necrotic damage. The majority of
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NEC cases can be managed medically, with bowel rest, gastric decompression, and antibiotics.
These cases are typically referred to in the literature as “medical NEC”. However, in 20% to
30% of cases the disease has progressed to require surgical intervention to remove the necrotic
sections of the bowel (Gupta & Paria, 2016). Infants who require surgical intervention, typically
referred to in the literature as “surgical NEC,” have a 30% mortality rate (Abdullah et al., 2010).
The risk of developing NEC and experiencing mortality is inversely related to the infant’s
birthweight (Fitzgibbons et al., 2009).
NEC is not only clinically devastating. It is also costly. In 2002, a case-control analysis
measured the total hospital cost and length of hospitalization associated with a diagnosis of NEC
(medical or surgical) analyzed against a similar subject pool who did not develop NEC
(Bisquera, Cooper, & Berseth, 2002). The research team noted that that medical NEC required
22 additional days of hospitalization, whereas surgical NEC required 60 additional days of
hospitalization. Furthermore, medical NEC was associated with additional costs of $73,700 per
case, whereas surgical NEC was associated with additional costs of $186,200 per case (Bisquera
et al., 2002). More recent studies also support the findings of Bisquera et al. (2002).
In 2015, a prospective observational study funded by the National Institutes of Health
(NIH) reported on fiscal aspects of NEC treatment (medical or surgical) (Johnson, Patel, Bigger,
Engstrom, & Meier, 2015). Johnson et al. (2015) noted that NEC was associated with an
additional mean cost of $43,818. Additional costs were attributed to longer lengths of stays (85 ±
36 days with NEC compared to 70 ± 33 without NEC [p = 0.022]), and greater utilization of
resources. Microlevel cost data revealed that the highest cost contributors came from pharmacy
(11,900 ± 11,830 with NEC compared to 5,080 ± 4,194 without NEC [p = 0.005]), laboratory

Medicaid Reimbursement

6

and pathology (5,058 ± 3,756 compared to 2,698 ± 2,053 [p = 0.002]), and respiratory therapy
(6,815 ± 6,677 compared to 4,395 ± 6,073 [p = 0.045]).
The clinical and fiscal impact of NEC is not limited to the neonate’s initial
hospitalization. Neonates who survive NEC require specialized follow up to ensure optimal
neurodevelopmental outcomes, and have complex healthcare needs following discharge. A 2017
retrospective review reported that VLBW neonates diagnosed with NEC (medical or surgical)
had a higher risk of experiencing severe and moderate neurodevelopmental disabilities than
when compared to a similar cohort without NEC (Fullerton et al., 2017). Additionally, former
VLBW neonates who had NEC “frequently require rehospitilization after their initial discharge”
(Fullerton et al., 2017, p. 104). Higher utilization of health care resources is not limited to
rehospitilization. NEC survivors are likely to require home apnea and/or cardiorespiratory
monitors, home oxygen, gastronomy tubes, and nasogastric feeds (Fullerton et al., 2017). The
mortality, cost, short-term morbidity, and long term sequelae associated with NEC warrant full
utilization of the clinical recommendations aimed at disease prevention and early intervention.
Investigators describe NEC as a “potentially preventable morbidity” (Johnson, Patel, Jegier,
Engstrom, & Meier, 2013, p. 243).
Researchers state succinctly: breast milk is “the gold standard for preventing NEC in
preterm infants” (Papillon, Castle, Gayer, & Ford, 2013, p. 268). The AAP states, “mother’s own
milk is preferable for routinely feeding all preterm infants” (American Academy of Pediatrics,
2012). Unfortunately, both the physiological and emotional stress of having a child born
prematurely are barriers to providing exclusive MBM nourishment to premature infants (Callen
& Pinelli, 2005). In the NICU, only 28% of all mothers can provide an exclusive MBM diet,
leaving the majority of women to rely upon supplementation (Carroll & Herrmann, 2013). If
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MBM is not available, the AAP recommends PDHM as a supplement until MBM supply has
become consistent. The AAP further recommends that PDHM should only be obtained through
an established, reliable human milk bank (American Academy of Pediatrics, 2016).
Donor Milk
Historically, donor milk was provided by a wet nurse. However, during the late 19th
century, improvements in “sanction, plumbing, refrigerators, and canned sterile formula,” along
with the availability of animal milk, led to more widespread use of bovine-based formulas.
(Obladen, 2012, p. 227; Stevens, Patrick, & Pickler, 2009). Gradually during the early 20th
century, the “once highly organized” profession of wet-nursing waned, while “modern” methods
of providing nutrition were embraced (Stevens, Patrick, and Picker, 2009). As formula became
popular, some physicians sought safer ways to store and preserve human milk. Hence, the
creation of a milk bank, where women could donate their excess milk to a hospital for the benefit
of hospitalized infants.
The first donor milk bank was established in Vienna in 1909 (Jones, 2003). The first
mention of donor milk is credited to Dr. Hobbler (according to Miracle, Szucs, Torke & Helft,
2011) who noted the positive effects that “donor banked milk” had on fragile infants (Hoobler,
1914). The first American milk bank was established in Boston in 1919. During the early 20th
century, donor milk grew in popularity. By 1939, there were 12 established milk banks in North
America. During the 1950s and 1960s, natural breastfeeding was seen as inferior to formula, and
milk banking in North America declined. By the early 1980s, this trend had shifted, and there
were 53 milk banks in North America (Jones, 2003). During the HIV/AIDS crisis in the mid1980s, donor milk was seen as a potential vector for transmission, and support for PDHM
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quickly declined. This culminated in the Canadian Pediatric Society (CPS) formally revoking its
prior support for milk banking in an official position paper (Jones, 2003).
Prior to the CPS’s withdrawal of support, milk bank operators in North America formed
the Human Milk Banking Association of North America (HMBANA) to standardize operations
among milk banks, thereby ensuring quality and safety. HMBANA collaborated with the Centers
for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and
the AAP to identify practices to safely accept, process, store and distribute human milk. In 1990,
the first edition of HMBANA’s Guidelines for the Establishment and Operation of a Donor
Human Milk Bank was published. The guidelines articulated evidence-based practices for safe
collection, storage, and distribution of human milk. Adoption and adherence to the guidelines
were initially voluntary but “set a standard for operation below which milk banks should not
fall” (Arnold, 2002, p. 353). HMBANA’s guidelines legitimized the practice of milk banking,
allowing for donated milk to gain medical acceptance as a therapeutic agent. K.W. Swanson
(2014) observed in her book “Banking on the Body: The Market in Blood, Milk, and Sperm in
Modern America” that “increased medical acceptance of banked milk at the turn of twenty-first
century” had the observable effect of “a new boom in milk banking” (p. 194).
Current Milk Bank Operating Structures
Milk banks currently operate within two frameworks: nonprofit and for-profit.
Nonprofit. There are currently 24 nonprofit milk banks operating within the United
States, all of which comply with HMBANA’s standards. The 24 nonprofit milk banks in the
United States, as well as the 2 operating in Canada, comprise HMBANA. As of 2016 HMBANA
has provided 5.25 million ounces of PDHM to NICUs throughout North America (HMBANA,
2017). K.W. Swanson (2014) observed that HMBANA treats donated milk as “civic property” to
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be managed for “the public good” (p. 196). Swanson’s observations of HMBANA’s operations
align with the Organization’s mission:
“[to advance] the field of non-profit milk banking through member accreditation,
development of evidence-based best practices, and advocacy of breastfeeding and human
lactation to ensure an ethically sourced and equitably distributed supply of donor human
milk” (HMBANA, 2016).
A 2017 featured story in The Atlantic described the process to become a donor to a HMBANA
milk bank as “extensive” (Schreiber, 2017). The screening process includes multiple phone
interviews, medical clearance for both members of the dyad, maternal blood work, and the
completion of detailed questionnaires. Once a donor is deemed acceptable she is able to donate
surplus milk to the milk bank.
Donated milk is screened for infectious agents. After the donation is deemed safe, milk is
pooled into aliquots for pasteurization. Pooled pasteurized milk is screened once more for any
infectious agents prior to being frozen for distribution.
HMBANA milk banks do not place a fiscal value on the milk they distribute. They do
however charge a processing fee to the ordering entity. The processing fee provides
reimbursement for the costs incurred to screen donors, effectively pasteurize, and ship the milk
(i.e. operational and distributive costs). Costs range from $3.00/ounce to $5.00/ounce.
For-profit. For-profit milk banks (i.e., Prolacta BioScience, Medolac Laboratories, NiQ) pay for a mother’s expressed breast milk (approximately 1 dollar/once). The expressed breast
milk is used in a lactoengineered patented product exclusive to the for-profit milk bank. Forprofit milk banks vary in what they produce. Some produce (or are attempting to produce)
PHMF, while others specialize in creating shelf stable human milk that does not require
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refrigeration. Currently Prolacta BioScience is the only company capable of producing PHMF.
The cost of Prolacta’s PHMF is $6.25/milliliter, and Prolacta sells PDHM for $9.50 per ounce
(C. Schmaltz, personal communication, November 4, 2017). Companies that produce
lactoengineered products have been described as following a “market property model, selling
bottled milk for the benefit of its shareholders” (Swanson, 2014, p. 195).

Current Support
No federal reimbursement practices comply with AAP guidelines or the surgeon
general’s support of PDHM to VLBW neonates when MBM is unavailable (U.S. Department of
Health and Human Services, 2011). State reimbursement practices remain inconsistent. Lack of
federal reimbursement practices motivated the National Association of Neonatal Nurses (NANN)
and the AAP to release position statements encouraging health care providers to advocate for
donor milk reimbursement (American Association of Pediatricians, 2016; National Association
of Neonatal Nurses, 2016). NNAN’s Health Policy & Advocacy Committee recognizes that
private insurance historically reflects Medicaid reimbursement practices and have recommended
local advocates to champion the inclusion of human milk into their states’ Medicaid’s
reimbursement structure (National Association of Neonatal Nurses, 2016).
Review of the Literature
Since 1881, experts have articulated support for breast milk. Formal support for breast
milk was initially derived from expert opinion, formulated from observations in clinical practice.
Since the late 19th century, the body of evidence supporting breast milk as the ideal form of
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nutrition for a neonate (particularly an ill neonate) has become irrefutable, due to a robust body
of scientific research.
The first published statements concerning the value of human milk over other nutritional
regimens were published in the Journal of the American Medical Association (JAMA) during the
summer of 1888 (Warrington Earle, 1888). In an article entitled “Infant Feeding,” Dr. Earle
introduced the work of German Physician Adolf Aron Baginsky to the American Medical
community. Baginsky’s clinical observations and recommendations were put forth in his
published work “Kinderkrankheiten” (Children’s Illness). In Kinderkrankheiten (according to
Earle) Baginsky identifies maternal breast milk (MBM) as the best nutritional source for
neonates, followed by a ‘wet nurse.’ Dr. Warrington Earl continued to elaborate that Baginsky’s
observations were developed in Berlin, where “half of all children born out of wedlock die
within six months” due to a lack of access to human milk (Warrington Earle, 1888, p. 150).
Warrington Earle proposed to the American medical community that if MBM “cannot be
furnished, in large cities at least, a wet-nurse should be procured” (Warrington Earle, 1888, p.
150). Following the publication of Baginsky’s expert opinion, it would take 25 years for the
American medical community to be exposed to a stronger form of evidence: outcome research.
In 1913, Davis conducted the first American outcome research study investigating the
effectiveness of MBM vs formula. Davis analyzed death records and survey responses. He
concluded that subjects exposed to formula had a mortality rate six times higher during the first
year of life than subjects who received MBM (Davis, 1913). Davis warns readers that
“advertisement of infant foods” have “lulled both other and physicians into a false sense of
security in the practice of artificially feeding” (p. 234). Davis speculates that “a full third of all
infant’s deaths” can be attributed to “unnecessary bottle feeding” (Davis, 1913, p. 234).
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Dr. Davis was not alone in his concern for displacing MBM in an infant’s diet. In 1917,
Dr. J.P. Sedgwick, Professor of Pediatrics at the University of Minnesota, stated “the real cause
of most of the unnecessary infant” deaths was a lack of human milk. Dr. Sedgwick also
commented that a “lack of interest” from his colleagues regarding optimal nutrition for a neonate
may be a reason that proper scholarly investigation and clinical implementation had yet to occur
(Sedgwick, 1917, p. 22).
While the early published reports and expert recommendations could be dismissed as
observational, and unscientific, they do form the foundation for scholarly inquiry to investigate
an optimal nutritional intervention when MBM is not available.
The safety of PDHM for patients in the modern NICU was first established by Davies
(1977), and later reinforced by Schultz, Soltesz, and Mestyan (1980). Neither Davies (1977) nor
Schultz et al. (1980) reported adverse events within the treatment group exposed to donor milk.
However, Davies (1977) did note that subjects who received the intervention demonstrated a
growth pattern that lagged behind the formula control group. Thus, some clinicians are skeptical
that an exclusive human milk diet (MBM and/or PDHM) will provide sufficient calories. Human
milk caloric concentration varies, so the skepticism is warranted.
Knowledge of the dynamic nature of human milk coupled with the findings of Davies
(1977) influences the astute clinicians’ daily evaluation of the VLBW neonate’s nutritional
status. Ideally a VLBW neonate will experience a growth trajectory within the NICU that would
mirror third trimester intrauterine growth. Failure to balance caloric expenditure with caloric
intake results in postnatal growth failure. For the VLBW neonate, postnatal growth failure may
have detrimental long-term consequences. When a VLBW neonate has the potential to
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experience a negative caloric balance, caloric fortification should be added to the enteral
nutrition (Prince & Groh-Wargo, 2013).
Prior to 2009, the only option to increase the caloric concentration of human milk was the
addition of a bovine-based protein. Lactoengineering advances now make it possible to continue
an exclusive human milk diet when additional calories are required. To increase the caloric
density of human milk, clinicians have the ability to utilize pasteurized human milk fortification
(PHMF) to meet the nutritional needs of the VLBW neonate. PHMF is lactoengineered PDHM.
During lactoengineering, macronutrients within the PDHM are concentrated, resulting in the
production of PHMF. When additional calories are required to meet the patient’s nutritional
needs, PHMF can be added to MBM or PDHM, or to a combination of the two milk bases
(Prince & Groh-Wargo, 2013).
Clinical Benefits
In 2014, the Cochrane Library published a systematic review of formula and donor milk
(Quigley & McGuire, 2014). The primary objective was to evaluate effects of PDHM and
preterm formula on anthropometric data. Secondary analysis included investigation of NEC rates
between the two nutritional regimens. The primary objective (growth) favored formula, however
the secondary analysis (NEC rates) favored PDHM. Quigley & McGuire (2014) reported a 2.7%
increase in the risk of developing NEC in infants fed formula compared to PDHM. While this
review is useful, it cannot be relied upon as the sole evidence to support the provision of PDHM
to the VLBW neonate. The inclusion of studies with a subject population above 1,500 grams
dilutes the patient population at highest risk for the development of NEC. Further, while the
primary objective (growth) favored formula, there was no evidence that the provision of PDHM
had any effect on post-discharge growth rates or neurodevelopmental outcomes. With a subject
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population above 1,500 grams, it is possible to underestimate the effects of sluggish postnatal
growth for the VLBW population.
Quigley and McGuire established the safety and efficacy of PDHM, yet the systematic
review was performed on a collection of studies conducted prior to widespread utilization of
lactoengineered products. Lactoengineered products enable clinicians to prescribe a nutritional
regimen free of formula or bovine based human milk fortifiers. Prior to lactoengineered
products, when postnatal growth was inadequate, clinicians could only increase the caloric
concentration of MBM and/or PDHM by utilizing a human milk fortifier constructed of bovine
protein. The nutritional strategy that utilizes bovine-based human milk fortifier added to MBM
or PDHM is known as a bovine fortification nutrition regimen (BFNR). Lactoengineering
enabled Prolacta BioScience to create pasteurized human milk fortification (PHMF). PHMF in
conjunction with MBM and PDHM permits clinicians to prescribe an exclusive human milk diet
(EHMD). Results from studies that examine BFNR vs EHMD support the elimination of nonhuman nutritional products for the VLBW neonate.
In 2010, a randomized control trial lead by Sullivan et al. (2010) sought to identify
whether EHMD (MBM, DBM, and PHMF) offers greater benefits than standard bovine-based
nutritional products (BFNR). Following the trial, Sullivan et al. (2010) reported a 77% reduction
in the odds of developing NEC with a EHMD (odds ratio = 0.23, 95% confidence interval 0.080.66). While EHMD could not eliminate the risk of developing NEC, the intervention can be
credited with decreasing the severity of NEC. EHMD incidences of medical NEC at 6% (n=8)
and surgical NEC of 1% (n=2) vs BFNR where medical NEC was observed in 16% (n=11) and
surgical NEC 10% (n=7) (p=0.007; p value set at 0.05).
Hair et al.’s (2016) multicenter retrospective study further emphasizes the benefits of
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EHMD. Hairs et al.’s study consisted of 1,587 VLBW infants within the United States. NEC and
mortality were the primary outcome measures. Subjects received enteral nutrition of either
EHMD or BFNR. Subjects who received EHMD had significantly lower rates of NEC (6.9% vs.
16.7%, p < 0.00001) and mortality (13.6% vs. 17.2%, p = 0.04) when compared to subjects who
received BFNR. The results of Quigley and McGuire (2014), Sullivan et al. (2010), and Hair et
al. (2016) demonstrate the clear clinical benefits of providing PDHM and PHMF to the VLBW
population.
Fiscal Benefits
In 2002, Arnold proposed the provision of PDHM to hospitalized neonates as a costsaving measure. “The cost of using banked donor milk to feed premature infants is
inconsequential when compared to the savings from NEC prevention” (Arnold, 2002, p. 172).
Arnold speculated that both health care systems and health care payers would experience a cost
savings following the implementation of PDHM into NICU. While Arnold’s proposals are
convincing, they lack the same statistical rigor later investigators would bring to the subject.
In 2012, a cost analysis by Ganapathy, Hay, and Kim concluded that EHMD resulted in a
direct fiscal savings of $8,167 per infant while contributing to a “societal value” of “reducing
infant mortality” (p. 36). Ganapathy et al. (2012) reached their conclusion by developing a cost
analysis framework, described by the research team as a ‘calculator.’ The calculator was a
mathematical algorithm that utilized constraints and benchmarks for analysis.
The following constraints were utilized to develop the calculator:
1. Probability of developing NEC following exposure to a EHMD vs. BFNR
2. Severity of NEC following exposure to a EHMD vs. BFNR
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3. Prices of bovine based preterm formula and bovine based fortifier required to provide
a BFNR
4. Prices of PDHM and PHMF required to provide an EHMD.
5. Volume of bovine based preterm formula and bovine based fortified requires to
provide a BFNR
6. Volume of PDHM and PHMF required to provide an EHMD.
Constraints 1 and 2 were taken from the results of Sullivan et al. (2010). Constraints 3
and 4 were a conservative estimate utilizing the lowest commercial prices available. Constraints
5 and 6 were taken from the reported median from Sullivan et al. (2010).
The following were utilized as benchmarks utilized for analysis (this data was obtained from
California’s Office of Statewide Health Planning & Development (OCHPD)):
1. Average cost of hospitalization for a VLBW neonate without NEC
2. Average cost of hospitalization for a VLBW neonate with NEC
3. Average cost of hospitalization for a VLBW neonate with NEC who requires
surgical intervention
Following a clear identification of the constraints and benchmarks, a data sample was
required to “plug into” the calculator. Ganapathy et al. (2012) utilized the discharge coding from
California’s 2007 OSHPD database to construct the data sample. With an established data
sample, Ganapathy et al. (2012) were able to run their calculator (see Table 3). The fiscal savings
of $8,167, while impressive, is likely a conservative estimate. While the cost calculator did
account for the hospital charges resulting from the NEC diagnosis, the cost calculator did not
take into account for the long-term sequela and health care resource utilization survivors of NEC
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have been documented to have (Fullerton et al., 2017). Findings from Ganapathy et al. (2012)
run parallel to recent reports.
In 2016, Assad, Elliott, and Abraham reported a cost savings of $54,511 per VLBW
neonate following implementation of EHMD within a single health care institution. The cost
savings began when the NICU changed their nutritional approach to center around human milk.
Assad et al. (2016) reported that while BFNR (with limited PDHM) was the unit’s standard of
care the average cost of hospitalization per VLBW neonate was $292,158. Once EHMD was
introduced, measurable improvements were noted (decrease incidence of NEC, feeding
tolerance, utilization of parenteral nutrition). Clinical improvements translated into a decreased
average cost of hospitalization per VLBW neonate ($237,647) following the adoption of a
nutritional strategy that emphasized human milk.
While the data presented by Ganapathy et al. (2012) and Assad et al. (2016) is
convincing, critics may not embrace Arnold’s notion that the cost of PDHM is
“inconsequential.” To strengthen the argument that providing reimbursement for PDHM would
result in a net savings in Medicaid dollars, advocates could create a calculator similar to
Ganapathy et al. (2012) utilizing state specific data.
Federal Policies
Advocating for public funding requires a working knowledge of the federal and state
agencies that are responsible for distributing funds. There are three federal programs that support
human milk consumption and lactation: Medicaid, the State Children’s Health Insurance
Program (CHIP), and the Special Supplementation Program for Women, Infants and Children
(WIC). In addition to federal programs, the Patient Protection and Affordable Care Act ensures
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that lactating women have access to supportive services and devices (breast pumps) at no
additional cost.
Medicaid
Optimizing federal support for the medically fragile was a key initiative of President
Lyndon B. Johnson’s administration. The Social Security Amendment of 1965 funneled federal
resources into the healthcare sector through two programs, Medicaid and Medicare (Teitelbaum
& Wilensky, 2017). Since its enactment in 1965, policy makers and legislators have continuously
analyzed ways to use the program to address the public’s fluctuating health needs. Congress
routinely adjusts eligibility criteria, covered services, and program financing as policy makers
seek to optimize Medicaid’s performance.
One of Medicaid’s strengths is its adaptability. Medicaid was designed as a partnership
between the federal and state government to create a health insurance program based on need.
Need-based programs are often described as “means-tested benefits” because eligibility for
services require participants to demonstrate a need for government support (Teitelbaum &
Wilensky, 2017).
Due to Medicaid’s partnership design between federal and state agencies, it is essential
for health care advocates to conceptualize “fifty-six different Medicaid programs – one for each
state, territory, and the District of Columbia,” rather than a prescriptive monolithic insurance
carrier (Medicaid and CHIP Payment and Access Commission, 2017). The federal government
mandates some benefits states must fulfill, but there is a great deal of flexibility and discretion
provided to the states in designing an optimal benefit package for their enrollees. States are fully
empowered to expand or contract non-mandatory benefits to accommodate their residents’ needs.
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States are also free to require Medicaid recipients to cost- share in return for program
participation (Wachino, Schneider, & Rousseau, 2004).
Prior to 2012, all states participating in the Medicaid program were required to design
eligibility packages to include “pregnancy-related services.” However, the term “pregnancyrelated services” created policy ambiguity about whether lactation services were required. The
Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid
Services (CMS) released a joint statement clarifying that “pregnancy-related services” include
lactation services (Centers for Medicare & Medicaid Services, 2012). The HHS and CMS
statement allowed states to receive federal matching reimbursement funds for lactation
consultants, examination of a lactating mother, breast pump rental, and breast pump purchase
(Centers for Medicare & Medicaid Services, 2012). However, the joint statement did not address
the special needs of the lactating mother of a VLBW neonate. Nor did the joint statement address
access to human milk if MBM is not available or sufficient.
State Children’s Health Insurance Program (CHIP). In 1997 policy makers addressed
the health insurance needs of “children whose family income is above the eligibility for
Medicaid in their state” (Teitelbaum & Wilensky, 2007, p. 215). While participation is optional,
all 50 states participate, and receive matching funds from the federal government.
CHIP was designed to be a flexible source of insurance for qualifying recipients. States
have the option to extend CHIP coverage to pregnant women (March of Dimes CHIP, 2016).
While there is no specific language for states to utilize federal funds for a reimbursement
structure to pay for costs association with breastfeeding, states do have the ability to channel
matched federal funds into breast feeding programs/services for CHIP.
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Special Supplemental Program for Women, Infants, and Children (WIC).
Established in 1974, WIC has become recognized nationwide as a valuable program to ensure
economically disadvantaged women, infants, and children have access to “food, nutrition
counseling, and access to health services” (United States Department of Agriculture Food and
Nutrition Services, 2016). The legislative appropriation process annually funds WIC. The
Department of Agriculture’s (USDA) Food and Nutrition Service provides oversight for the WIC
program, and ensures that funds appropriated from Congress are disseminated to the states. State
agencies have a great deal of flexibility to create food packages to accommodate participant
preferences and cultural practices. However, all food packages approved by the state must adhere
to federal guidelines to assure the provision of adequate nutritional value (Revisions in the WIC
food packages Federal Register, 2014, p. 12274). WIC also provides breastfeeding support.
WIC’s organizational structure permits experts to be available at both the state and local level “to
maximize efforts to promote, support, and manage breastfeeding as the preferred feeding method
for all infants” (AAP, 2001, p. 1216).
The Patient Protection and Affordable Care Act (PPACA). The PPACA was enacted
in 2010 to manage costs and ensure the availability of quality health insurance plans. The
PPACA requires all private plans to provide specific preventive care measures without cost
sharing (Section 2713 of PPACA, 2010). Services required to ensure an exclusive human milk
diet for a healthy term neonate are one of the protected preventive care measures. Health plans
created after the enactment of the PPACA must cover breastfeeding support, pumping supplies,
and lactation counseling with no cost sharing (PPACA, 2010). The inclusion of lactation supplies
and support enables families to advocate for and provide an exclusive human milk diet for a
healthy term neonate. However, the ACA does not include utilization of PDHM to supplement
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MBM when an infant is in the NICU. Thus, there is no federal mandate to ensure private
insurance policyholders will be reimbursed for PDHM.
Despite current reimbursement practices, the federal government does have a history of
publicly funding PDHM. On March 1, 2000, the Federal WIC program ceased payment
reimbursement for PDHM (National Association of WIC Directors, 2000). When public funding
for PDHM was terminated, Agriculture Undersecretary Shirley R. Watkins mentioned the
decision was due in part to the relatively small number of patients who require PDHM. She also
suggested that, due to a lack of federal oversight within the HMBANA milk banks, quality could
not be assured, leaving the federal government potentially liable (Watkins, 2000). While no
federal agency provides direct oversight of HMBANA milk banks, the FDA recognizes
HMBANA’s safety guidelines and directs parties concerned with screening donors or the safe
collection, processing, testing, and storage of human milk to the HMBANA webpage (Food and
Drug Administration, 2016).
Georgia Policies
In Georgia, there are no reimbursement practices (private or public) to support the
provision of an exclusive human milk diet to the VLBW patient population. Both the AAP and
NANN have published calls to action for members to become local advocates to urge
policymakers to enact reimbursement policies to remove (actual or potential) cost barriers
prohibiting full utilization of human milk within the NICU. The AAP and NANN have directed
advocates to focus efforts on their states’ Medicaid structure to enact PDHM reimbursement
policies (American Academy of Pediatrics, 2016; National Association of Neonatal Nurses,
2016). Prior to enacting an advocacy campaign, it is prudent to determine if there are other
avenues in the state (i.e. CHIP) that might be able to provide a reimbursement structure.
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Georgia Medicaid
Georgia’s Medicaid budget comes from two sources: the federal government, and state
monies allocated to the Department of Community Health. Historically, the annual proposal from
Georgia’s governor to the state’s legislative body has fluctuated to reflect the available matching
funds provided by the federal government. However, Georgia’s Medicaid program can be
infused with additional funds separate from the federal government or a proposal from the
Governor. Tax revenue and monies obtained in legal settlements can also be infused into the
DCH. Under the current structure, the majority of the DCH budget is utilized for Medicaid and
Georgia’s CHIP program (PeachCare) (Georgia Budget & Policy Institute, 2017).
In the 2018 budget, $4.5 billion USD of state funds are allocated to healthcare. The
healthcare division of the Georgia state government is comprised of the Department of
Community Healthy (DCH), the Department of Public Health (DPH), and the Department of
Behavioral Health and Developmental Disabilities. Of the total funds allocated for the health
care sector, $3.1 billion USD (70%) is designated to go to the DCH. The DCH is responsible for
managing Georgia’s Medicaid and CHIP (PeachCare for Kids) programs. In addition to state
funds, Georgia’s Medicaid and PeachCare also receive federal funds to ensure fiscal solvency. In
2018, Georgia’s Medicaid and PeachCare will operate with state funds of $3.1 billion USD as
well as $7.2 billion USD federal money for Medicaid, and $461 million USD for PeachCare.
Currently every dollar Georgia spends on Medicaid is matched by $2.71 USD in federal funds.
(Georgia Budget & Policy Institute, 2017).
Neonates receive automatic enrollment for Medicaid coverage when they meet one or
more of the following conditions: (a) born to a mother who receives Medicaid; (b) born to a
mother who receives PeachCare for Kids; (c) born to a mother who receives Emergency Medical
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Assistance; and (d) placed for adoption or requires foster care (Georgia Department of
Community Health, 2016). Medicaid is the primary payer for the majority (54%) of neonates in
Georgia (Kaiser Family Foundation, 2017).
Georgia’s CHIP plan. PeachCare for Kids (Georgia’s CHIP Program) provides coverage
to legal residents of Georgia who are between the ages of 0 and 19. Eligibility depends on
household size and income. PeachCare for Kids does not provide any services to an eligible
member after their 19th birthday. Nor does it offer services to the unborn or to hospitalized
neonates. PeachCare for Kids will provide for pregnancy-related services if an enrolled adolescent
becomes pregnant (Georgia Families Medicaid & PeachCare for Kids, 2017).
WIC in Georgia. In 2017 Georgia received $68,207,168 to cover all eligible WIC
recipients (United States Department of Agriculture Food and Nutrition Services, 2017).
WIC is administered to enrolled recipients through the Georgia Department of Public Health.
Georgia WIC maintains at least one community health center per county (Georgia has 159
counties, and maintains 993 clinics) (Georgia WIC, 2017)
Engagement options for Georgia. Georgia’s Medicaid Program is currently best
equipped to absorb a policy inclusion that pertains to the VLBW hospitalized neonate. The
following strategies could offer Medicaid reimbursement for human milk provided to VLBW
neonates: (a) enact legislation mandating that Georgia’s Medicaid Program adopts
reimbursement for human milk; or (b) include a budget for human milk into the state’s current
reimbursement practices.
The inclusion for PDHM into Georgia’s existing Medicaid structure would go through
the Georgia Department of Community Health (DCH). Georgia’s DCH is the single state agency
responsible for overseeing and distributing Georgia’s Medicaid funds. In Georgia, the DCH
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proposes an annual budget (on behalf of the governor) for total Medicaid expenditures to be
voted upon by the legislature (Georgia Department of Community Health, 2012).
Providing reimbursement for PDHM would be a regulatory policy change within the
DCH, to be approved by the Chief of the Medicaid Division. On September 15, 2017, Blake
Fullenwider became the chief of the Medicaid Division in the Georgia Department of
Community Health (Press Release DCH, 2017). Mr. Fullenwider is responsible for
reimbursement policies (medications, preventive therapies, and diagnostic tests) for Georgia’s
Medicaid programs. After the director has approved the policy change, monies from the
discretionary budget would be reallocated for PDHM until a formal inclusion into the budget
occurs (Georgia Department of Community Health, 2012).
Billing and Coding
Advocating for donor milk reimbursement requires fluency with medical billing and
coding. Hospitals use standardized codes to describe the services/procedures/supplies provided
to the patient. Billing specialists utilize the medical chart to ensure that the standardized codes
submitted on a medical bill are supported by clinical documentation. To standardize bill
preparation and interpretation, the Centers for Medicare and Medicaid created the UB-04 form.
The UB-04 form enables the billing entity to ‘plug in’ the standardized codes into the appropriate
‘code field’ and submit the bill to the payer (Falen & Liberman, 2009).
Standardized codes include: (a) International Classification of Diseases, Tenth Revision,
Clinical Modification/Procedure Coding System (ICD-10-CM/PCS); (b) Current Procedural
Terminology (CPT); (c) Healthcare Common Procedure Coding System (HCPCS); and (d)
Revenue Codes; (e) National Drug Codes (NDC).
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ICD-10-CM/PCS was implemented in the United States after the Centers for Medicare &
Medicaid desired billing to capture a clinical presentation with increased specificity. Coding for
the diagnosis or a procure must be properly documented within a provider-generated note in the
patient’s chart (Chabra, 2015; Harding, 2015).
CPT codes are developed, copyrighted, and maintained by the American Medical
Association (AMA). The CPT code is a five-character numerical sequence that corresponds to a
specific procedure or service provided by a health care practitioner. The CPT system allows a
code to be appended with a two-character modifier if the clinical circumstances or procedure
warrant additional coding for payer compliance (Falen & Liberman, 2009; Harding, 2015).
The Centers for Medicare & Medicaid developed HCPCS for reporting procedures and
services. HCPCS represent medical procedures, services, and supplies to Medicaid, Medicare,
and insurance companies. HCPCS is composed of three different levels.
Level I HCPCS codes represent health care practitioner services. Level I HCPCS codes
are identical to CPT codes and are submitted to Medicare or Medicaid to provide reimbursement
for services. Level II HCPCS codes are used to request reimbursement for non-health care
practitioner services. Level II HCPCS codes include durable medical equipment, ambulance
rides, and mobility tools. While CPT and Level I HCPCS describe services and procedures,
Level II HCPCS describes the products used to deliver the services and products. Level III
HCPCS codes are used by state Medicaid agencies or Medicaid Contractors. They are not
nationally recognized. Georgia does not use level III HCPCS codes utilized for purposes of
reimbursement (Centers for Medicare & Medicaid Services, 2013).
Revenue codes are a sequence of numbers indicating where the procedure/service took
place (which department/unit) or the type of item provided to the patient by the hospital.
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Revenue codes were created for the Medicaid system, but have been adapted for widespread
hospital use. Medical claims that do not have a revenue code attached are rejected by payers.
Patients within the NICU are identified by a revenue code depending on the level of care they
require.
An NDC is a unique sequence of numbers used to identify any pharmacological agent
designed for human use. Each NDC is created by three specific sequences of numbers. The first
sequence of numbers is known as the labeler and is assigned by the Federal Drug Administration.
The second and third sequence is known as the product and package code. The product and
package code is created by the manufacturer. There are no NDC associated with human milk or
products created from human milk (Food and Drug Administration, 2017).
Establishment of a Medicaid reimbursement structure in the state of Georgia will require
a recognizable reimbursement code. Code T2101- Human breast milk processing, storage and
distribution is a Level II HCPCS code that pertains to PDHM. Two states (Texas and California)
and Washington D.C. currently utilize T2101 to process reimbursement claims. However, in
Texas, a special revenue code is attached to T2101 to indicate that the patient is requiring NICU
care. Although there are no ICD-10-CM/PCS or CPT codes associated with the provision of
PDHM, the aforementioned codes could be used to identify premature neonates who are at highrisk for NEC and likely received PDHM and/or PDMF.
Implementing a coding process similar to Texas would be a reasonable administrative
strategy for Georgia to adopt if policy makers were to allow PDHM to be reimbursed by
Medicaid. Unfortunately, no state has yet to adopt a uniform policy to enable hospitals to seek
reimbursement for PDMF. The absence of a policy surrounding PDMF reinforces current cost
barriers.
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Chapter Three

This chapter describes the proposed methods for achieving the project’s purpose,
promoting Georgia Medicaid reimbursement for donor milk to VLBW neonates. To ensure
scholastic integrity details regarding the collection of evidence will be presented along with the
proposed methodology for achieving the project’s aims. This chapter will also set forth an
evaluation plan, implications the proposed scholarship will have upon completion, and how the
scholarship will be integrated into the leadership immersion practicum.
Methodology
Approach to the Literature Review
A summary of the evidence supporting the utilization of PDHM within the clinical setting
was presented in Chapter 2. Evidence was identified utilizing a literature review of peer
reviewed data. The literature review was designed to achieve two objectives:
1. identify published studies that utilized an exclusive human milk diet or donor milk as
an intervention, measured against formula supplementation;
2.

identify published pharmacoeconomic reports which describe the fiscal expenditures
before and after implementation of an exclusive human milk diet.

Four different databases were utilized to ensure interdisciplinary representation. The
literature review included following databases: PubMed (life sciences and biomedical), CINAHL
(nursing and allied health), PAIS (social sciences), and Scopus (peer-reviewed publications
across scholarly disciplines). Within each of the aforementioned databases, the following terms
were utilized: donor human milk, donor breast milk, pasteurized human milk, exclusive human
milk diet, cost, neonatal, very low birth weight, benefit, outcomes, reimbursement, and policy.
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To narrow the results an exclusion criteria of the terms “(breastfeeding and/or breast feeding)”
was applied. Utilization of exclusion criteria was necessary to ensure only studies that fulfilled
the literature search were identified. Appropriate articles identified during the literature review
were summarized and placed within a detailed matrix. The literature review will provide the
clinical and fiscal evidence for the proposed manuscript “The Case for the Inclusion of Human
Milk into a state’s Medicaid Reimbursement Structure.”
Approach specific to Aim One. Describe current federal and Georgia state
reimbursement policies concerning human milk. The focus of Aim One is twofold:
1. Provide a detailed account of active federal, state, and milk banking policies that
affect utilization of PDHM; and
2. Describe the states that currently have Medicaid PDHM reimbursement policies to
inform a policy argument for Georgia Medicaid to reimburse for PDHM.
A formatted log will document the policy search (see Appendix A). Information collected during
this comprehensive policy search will be summarized into a policy matrix (See Appendix B).
Information regarding federal reimbursement and logistical oversight will be collected from:
1. The Agency for Health Research and Quality (AHRQ)
2. The Centers for Disease Control and Prevention (CDC)
3. Centers for Medicare and Medicaid Services (CMS)
4. The Department of Health and Human Services (HHS)
Georgia policies will also be addressed. At the state level, information regarding
reimbursement will be collected from the state Medicaid program. Documentation and
summarization of state policies will mirror the process used for the federal policies.
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Exploration of the practical logistical policies regarding the tracking, distributing, and
monitoring of PDHM not addressed by a government entity will be accounted for through the
investigation and summarization of milk banking practices.1
Approach specific to Aim Two. Utilize Coffman and Beer’s (2015) framework to
describe an ideal advocacy strategy that would lead to reimbursement for human milk by
Georgia Medicaid.
Coffman and Beer’s advocacy framework, “The Advocacy Strategy Framework: A tool
for articulating an advocacy theory of change” (ASF), was designed to illustrate a strategic
advocacy plan (See Figure 1). Information gathered from this project background & Aim 1 will
be integrated within the ASF to articulate an evidence-based rationale for the inclusion of PDHM
into Georgia’s Medicaid structure.
Coffman and Beer’s ASF emphasizes fluid interplay as the advocate engages with
stakeholders. It argues that “advocacy is not predictable or linear,” and encourages advocates to
engage in purposeful tactics when engaging to produce “meaningful interim outcomes”
(Coffman & Beer, 2015, p. 1). While advocacy engagement may not be “predictable or linear,”
to ensure the scholarly integrity of the project, advocacy field notes will be utilized to capture the
project’s progression (See Appendix C). Advocacy field notes will focus on the two constructs of
the ASF (audience members and change). Within ASF, audiences are the consumers of the
advocacy efforts. Audience includes members of the public (general or interested
parties), influencers of policy (media, businesses, collations, ect.) and decision
makers (individuals or groups responsible for policy adoption).
Change, the second construct within the ASF, is described as “the result [of] an advocacy
effort aim[ed]” at progressing the audience towards a policy goal. In the ASF change is
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conceptualized as a continuum, starting with awareness which grows into will and finally results
into action. Advocates utilize tactics to guide audience members through the continuum of
change. Advocacy tactics are how the advocate articulates the information to the audience, and
demonstrates policy support to the stakeholders (See Figure 2).
To ensure a flexible and comprehensive strategic framework, the ASF prompts advocates
to respond to the following questions:
1. How is the strategy positioned?
2. Who specifically is the strategy trying to influence and how?
3. What are the underlying assumption about how change happens?
4. Who else is working on this and how?
5. How will the strategy look in several years?
6. What interim outcomes are relevant to know if the strategy is on track?
Utilizing the ASF provides a framework for engagement, fosters organization and
productive momentum, and promotes a qualitative account of efforts enacted to achieve the
project’s goal (i.e. adopting reimbursement policies for an exclusive human milk diet to the
VLBW neonate).
To ensure a solid foundation for the advocacy campaign, this project will create
educational materials to increase audience recognition of the problem and familiarity with the
policy remedy. Educational materials will be distilled from the initial literature review and Aim
1. Proposed educational materials will include, but are not limited to: an opinion-editorial (that
will be submitted to a publication) and a policy brief, along with the proposed calculator. All
educational materials will be submitted to the project’s faculty advisor, Lisa Summers, DrPH,
FACNM for approval prior to utilization.2
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Approach specific to Aim Three. In collaboration with an economist, work toward the
development of a calculator that will permit Medicaid directors to unitize state-specific data to
demonstrate the cost effectiveness of providing an exclusive human milk diet.
As mentioned in Chapter 2, the creation of a calculator similar to the one presented in
Ganapathy et al. (2012) would be a powerful tool to demonstrate a net savings for Medicaid.
Ideally the calculator will permit advocates to utilize state-specific data to demonstrate the cost
effectiveness of providing an exclusive human milk diet. Aim Three will be a collaborative effort
between the Leonard Schaeffer Center for Health Policy and Economics at The University of
Southern California (USC) and Yale School of Nursing (YSN).
The mission for the Leonard Schaeffer Center for Health Policy and Economics at USC is
“to measurably increase value in health through evidence-based policy solutions, research and
education excellence, and private/public sector engagement” (USC Schaeffer Center, 2016). The
contact at the Leonard Schaeffer Center for Health Policy and Economics is Professor Joel W.
Hay. Dr. Hay is a Professor of Pharmaceutical Economics and Policy & a Professor of Health
Policy and Economics at USC. Dr. Hay was one of the main investigators for Costs of
Necrotizing Enterocolitis and Cost Effectives of Exclusively Human Milk-Based Produces in
Feeding Extremely Premature Infants.
Evaluation
The proposed scholarship will utilize formative qualitative evaluation along with
reflective journaling as assessment tools to guide the projects progress. Due to the dynamic
nature of advocacy work, two appraisal methods will be utilized to capture the totality of
engagement required for advocacy endeavors. Engagement with the assessment tools ensures
that the aforementioned aims contribute towards the project’s purpose (promote Medicaid
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reimbursement policies for PDHM provided to VLBW neonates in the state of Georgia) while
providing an opportunity to thoughtfully articulate actions and events that influence the project
once activated.
Formative evaluation. Effective formative evaluation can address unforeseen
complications within a project, empowering the advocate to make informed modifications while
remaining engaged in the process. An evaluation strategy that focuses on a singular outcome
goal minimizes the context of advocacy work. Instead, the proposed scholarship will be
evaluated at predetermined intervals. Predetermined evaluation is designed to provide a
structural approach during the campaign’s various stages: planning, active engagement with the
audience, and creating a proposed continuation for the advocacy efforts.
Staged formative evaluation will be reflective of Stetler et al. (2006) technique of
assessing and identifying the underlying disturbance (or potential disturbance) that must be
addressed to ensure the likelihood of achieving optimal impact. Stetler et al. (2006), recommends
that “action-oriented” projects engage in a series of four evaluation phases, each with a distinct
function. The four processes recommended by Stetler et al. (2006) are: developmental
evaluation, implementation-focused evaluation, progress-focused evaluation, and interpretative
evaluation. Developmental evaluation occurs during the planning phase of a project. Expected
obstacles are identified along with possible strategies to avoid project derailment. Once a project
has been “activated,” Stetler et al. (2006) recommend two form of evaluation: implementationfocused and progress-focused. Implementation-focused evaluation addresses the “discrepancies
between the plan and its operationalization,” while also encouraging the identification of
“influences that may not have been anticipated through developmental evaluation.” Progressfocused evaluation seeks to monitor the “indicators of progress” identified in the development
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phase of the project. Interpretative evaluation, the final process recommended by Stetler et al.
(2006), occurs once a project has results. The objective of interpretative evaluation is to
articulate the factors that affected the project’s results.
Stetler et al. (2006) proposal for formative evaluation phases can been succinctly paired
with key questions to summarize the evaluative stage (Dixon, 2017). The four questions are:
1.

What barriers do we expect? (i.e. developmental evaluation)

2. What are we actually doing? (i.e. implementation-focused evaluation)
3. How is it working? (i.e. progress-focused evaluation)
4. Why is it happening this way? (i.e. interpretative evaluation)
The four processes of formative evaluation recommended by Stetler et al. (2006) served
as the guide for developing the evaluation component for the proposed scholarly project. The
evaluation documentation plan can be found in the appendices (See Appendix D).
Reflective journaling. The Reflective Practitioner: How Professionals Think in Action
articulates the necessity to recognize that reflection is a hallmark of practitioners engaged in the
professional realm (Schön, 1983). Schön’s emphasizes that reflection enable practitioners to
justify the quality and rigor of purposeful actions while simultaneously providing a protective
opportunity by in allowing a possibility for corrective engagement (Schön, 1983). The
importance of reflection has been described in the Harvard Business Review as “an opportunity
to pause” to “sort through observations and experiences” and “consider multiple possible
interpretations” of events (Porter, J, 2017). Experts in the field of nursing also recognize the
benefit reflection has on the development of professional practice (Miller 2017 & Raterink
2016). Demonstrating a reflective process through journaling has been cited as a valuable tool
“that leads to the development and growth of judgment, personal values, and critical thinking”
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while “encourages the refinement of actions” (Miller, 2017). Proponents of reflective journaling
as a research tool highlight the qualitative process as “an instrument for diminishing the gap
between theory and practice,” while creating the opportunity for immediate feedback (Bashan &
Holsblat, 2017). The proposed scholarship will utilize journaling as an evaluation tool for
mentors and evaluators at YSN to interpret the project’s progression and provide opportunities
for ongoing appraisal of the advocate’s actions. The reflective journaling template is in the
appendices (See Appendix E).

Implications
The proposed scholarship is a direct response to the position statements set forth by the
American Association of Pediatricians and the National Association of Neonatal Nurses, which
call upon health care provides to advocate for donor milk reimbursement within their respective
states (American Association of Pediatricians, 2016; National Association of Neonatal Nurses,
2016). Completion of the policy matrices, and clear articulation of Coffman and Beer’s (2015)
ASF, and the calculator will serve as a foundation for advocates to mobilize in their states. The
process of completing this scholarship could also serve as a template for future Doctor of
Nursing Practice candidates to engage in scholastic advocacy work.
Leadership Immersion
Immersion related to the proposed scholarship will consist of:
1. Collaborating with Dr. Hay and his students at the Leonard Schaeffer Center for
Health Policy and Economics at The University of Southern California. The
collaborative effort will move toward (if not produce) a calculator that will permit
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Medicaid directors to utilize state-specific data to demonstrate the cost effectiveness
of providing an exclusive human milk diet.
2. Description of an ideal advocacy strategy (utilizing Coffman and Beer’s ASF) that
would lead to reimbursement for human milk by Georgia Medicaid. This strategy will
be formulated with the assistance of Suzanne Staebler, DNP, NNP-BC, FAANP, who
is an Associate Professor at Emory University.
3. Creation of the manuscript “The Case for the Inclusion of Human Milk into a State’s
Medicaid Reimbursement Structure.”

Statement Related to Human Subjects
During the developing stages of the proposed scholarly project, a summary was provided
to Yale University’s human research protection program. The project summary was reviewed
and discussed jointly with the Cathleen Montano, J.D., CIP, IRB (Yale’s IRB Manager) and
Monika Lau, M.Ed., CIP (Yale’s IRB-of-Record Specialist). Following a group discussion, it
was deemed unnecessary for “Nurse Driven Scholastic Advocacy: Medicaid Reimbursement for
Pasteurized Donor Milk” to seek IRB approval, because the project does not deal with human
subjects.
Scholarly Project Timeline
To maintain forward momentum, the following timeline is submitted to monitor
the progress of the proposed scholarship.
Activity

Completion Date

Comprehensive Federal Policy Search

May 25, 2018

Summarizing Federal Policies into a Policy Matrix

June 1, 2018
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Comprehensive State Policy Search

June 10, 2018

Summarizing State Policies into a Policy Matrix

June 20, 2018

Immersion Contract Completed, External Mentors Identified,
Immersion Objectives Approved

June 30, 2018

Completion of Educational Materials

July 15, 2018

Completion of Manuscript “The Case for the Inclusion of Human
Milk into a state’s Medicaid Reimbursement Structure”

September 30, 2018

Completion of Immersion

December 13, 2018

Scholarly Project Completion

February 20, 2019

Scholarly Project Manuscript uploaded to ProQuest

March 1, 2019

Scholarly Project Presentation

March 8, 2019

*Project Timeline is under negotiation.
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Chapter Four

The following chapter describes the project’s implementation and evaluation, a plan for
dissemination, and a reflection on interdisciplinary work.
Project Implementation and Evaluation
Aim One
The first aim entailed describing current federal and Georgia state reimbursement policies
concerning pasteurized donor human milk (PDHM). This aim’s objective was to identify and
describe current reimbursement and regulatory processes which influence clinical utilization of
PDHM.
Implementation. The formatted log (see Appendix A) guided the policy search of the
following federal agencies:
1. The Agency for Health Research and Quality (AHRQ)
2. The Centers for Disease Control and Prevention (CDC)
3. Centers for Medicare and Medicaid Services (CMS)
4. The Department of Health and Human Services (HHS)
The policy search for Georgia state included:
1. The Georgia Department of Community Health (DCH)
2. Georgia Department of Public Health (DPH)
Georgia’s DCH is tasked with providing Georgian’s access to “affordable, quality health
care,” and provides oversight to the state’s Medicaid programs, whereas the DPH focuses on the
protection and promotion of health (Georgia DCH, 2018; Georgia DPH, 2017). The remaining
24 agencies in Georgia have no direct oversight or impact on healthcare reimbursement or the
provision of healthcare services, and were therefore not included in the search.
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Policy search. The following terms guided the search for policies, documents, and
recommendations: “Pasteurized Donor Human Milk,” “Pasteurized Donor Breast Milk,” “Donor
Breast Milk,” “Donor Human Milk,” and “Pasteurized Breast Milk.” Results of the policy search
can be found in Appendix F. No regulatory or reimbursement policies were identified in the
policy search on either the federal or state level.
Evaluation. Currently, there are no federal or state policies that regulate the distribution
or utilization of PDHM. However, three federal agencies (AHRQ, CDC, and HHS) refer to
PDHM as an alternative over formula with varying degrees of support.
The Department of Health and Human Services (via the Food and Drug Administration
[FDA]). This agency takes no position regarding the utilization of PDHM; rather, it cautions
against informal milk sharing while stating that milk should be obtained through a reliable
operation which screens donors and ensures the safety of the milk distributed. The FDA does not
describe the process of screening donors or ensuring safety; however, it directs interested parties
to HMBANA.
The Agency for Health Research and Quality and the Centers for Disease Control and
Prevention. These agencies have released documents that identify a lack of uniform
reimbursement policies pertaining to PDHM. While the AHRQ and CDC have both released
documents articulating support of PDHM, only reports from the former directly refer to
published empirical data to support the claim that PDHM provides benefits to the very low birth
weight (VLBW) neonatal population.
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Aim Two
The second aim utilized Coffman and Beer’s (2015) framework to describe an ideal
advocacy strategy that would lead to reimbursement for PDHM by Georgia Medicaid.
Implementation. An ideal advocacy strategy was formulated with the assistance of
Georgia health policy expert Professor Suzanne Staebler, DNP, NNP-BC, FAANP. Coffman and
Beer’s (2015) advocacy strategy was utilized as a conceptual framework. Audience members for
the advocacy strategy are identified in Table 4. A pictorial representation of the articulated
advocacy strategy can be found in Figure 3.
Targeted implementation. Efforts arising from this project focused on the identified
decision makers. The evidence-based advocacy tool created from the third aim was utilized to
emphasize the fiscal benefits Georgia Medicaid would likely experience following adoption of
reimbursement policies for PDHM.
Aim Three
In collaboration with an economist, the third aim involved working toward the
development of a calculator that permits Medicaid directors to utilize state-specific data to
demonstrate the cost effectiveness of providing PDHM to VLBW neonates.
Implementation. The senior author of the publication “Costs of Necrotizing
Enterocolitis and Cost-Effectiveness of Exclusively Human Milk-Based Products in Feeding
Extremely Premature Infants” (Ganapathy, Hay, & Kim, 2012) was approached in March 2018
regarding the possibility of forming an interdisciplinary collaboration. The project aligned with
the scholarship of Jonathan Salcedo, M.A., a PhD student in pharmaceutical and health
economics. A telephone conference was held to ensure clear communication between members
of this interdisciplinary team and to articulate a joint commitment to the project on behalf of their
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doctoral students. In April 2018, the interdisciplinary collaborative arrangement was agreed upon
and Mr. Schmaltz and Mr. Salcedo began the process of developing a cost calculator.
It was agreed that the project would serve the following objective: to quantify the costs
and benefits of reimbursement for human milk by Georgia Medicaid. The cost and benefits
would be limited to the following intervention: supplementation of PDHM (intervention) vs.
preterm formula (control) when mother’s milk is unavailable. While the benefits of human milk
are numerous, careful selection of the target population provided the project with structure. It
was agreed that the target population would be: VLBW neonates (≤ 1500 grams) hospitalized in
the neonatal intensive care unit (NICU).
The following sections describe the methods utilized to create the cost calculator, the
results obtained, and the process of evaluating the results from the cost calculator.
Methods. A decision tree design provided the cost calculator with an operational
framework. The cost calculator was powered by a mathematical algorithm which applied
constraints and benchmarks to demonstrate total cost savings from a Medicaid program
perspective. Constraints for the model were obtained from randomized control trial data,
published longitudinal healthcare data, market pricing, and expert opinion. State-specific
hospitalization costs served to provide benchmarks for the model. To prove validity of the
calculator, results underwent a one-way deterministic sensitivity analysis and a multivariate
probabilistic sensitivity analysis. The cost calculator creation utilized Microsoft Excel, with
additional statistical analysis support provided by Visual Basic for Applications.
Data analysis plan. Data analysis sought to find the relation between intervention and
outcome. Fiscal savings were sought by analyzing constraints (intervention exposure, feeding
volume, feeding cost, and long-term costs associated with intervention) against identified
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benchmarks (state-specific costs of hospitalization, state-specific costs of medical necrotizing
enterocolitis, and state-specific costs of surgical necrotizing enterocolitis). Longitudinal fiscal
savings were sought at the intervals and metrics previously reported by Ganapathy et al. (2013):
1. Discharge from the hospital,
2. Discharge from the hospital to six months of age,
3. Six months of age to twelve months of age,
4. Twelve months of age to two years of age, and
5. Two years of age to three years of age.
The objective to quantify the costs and benefits of inclusion of PDHM into state
Medicaid reimbursement was achieved by evaluating the base case costs associated with subject
hospitalization prior to policy adoption (no exposure to the intervention) vs. costs associated with
subject hospitalization following policy adoption (intervention exposure). Base case costs can be
found in Table 5.
Results. Application of the data analysis plan resulted in cost savings at every
predetermined interval. Detailed results of costs following policy adoption and cost savings
following policy adoption can be found in Table 6 and Table 7. Images of the final evidencebased advocacy tool can be found in Appendix G.
Effects on reimbursement. From a Georgia Medicaid perspective, payers would likely be
cost-savings and at a minimum, program adoption would be cost-neutral.
Evaluation. The third aim underwent a formative qualitative and statistical quantitative
evaluative process.
Formative evaluation. The project’s process of formative evaluation occurred in three
distinct phases, each with a central focus and objective. Formative evaluation proved valuable in
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maintaining responsive engagement, providing a process to ensure optimal communication as
well as a method to allow team members to continuously evaluate the project’s process. Initially,
the qualitative process took the form of electronic communication through the creation and
dissemination of meeting minutes; however, as the members of the interdisciplinary team eased
into a more comfortable working relationship, the portions of formative evaluation were more
reliant upon phone calls and teleconference meetings. Formative evaluation during the
interdisciplinary project is summarized in Appendix H.
Statistical evaluation. Results underwent a one-way deterministic sensitivity analysis
(DSA) and multivariate probabilistic sensitivity analysis (PSA).
One-way deterministic sensitivity analysis. Application of a one-way analysis maintains
consistency of all variables except for one. This study’s one-way DSA is illustrated with a
Tornado diagram in Figure 4. The Tornado in Figure A places the cost (the one variable that is
being evaluated) on the x-axis against the model’s output (the measure of consistency) on the yaxis. DSA demonstrates that the adoption of PDHM reimbursement policies is beneficial for a
payer for the first 36 months of life.
Multivariate PSA is a statistical method which treats all input data as a random
occurrence. Running data through a multivariate PSA strengthens claims that an intervention will
result in a predicted outcome. Unlike DSA, where individual data points are augmented while
maintaining other variables fixed, PSA allows for all data points to depart from the base-case
value.
Multivariate probabilistic sensitivity analysis. Monte Carlo simulation estimates
outcomes (i.e., cost savings) by randomly sampling values from a distribution crated for each
variable in the model. This produces an estimate of the likelihood of cost savings, given the
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uncertainty of the specific value for each variable. Results demonstrated that adoption of PDHM
reimbursement policy would be a cost-saving intervention for VLBW neonates during the first
36 months of life (see Table 8).
Dissemination
Scholarship surrounding the project also resulted in:
1. A poster presentation at the 2018 International Congress on Human Milk Banking
2. A poster presentation at the International Society for Pharmacoeconomics and
Outcomes (ISPOR)
3. A manuscript titled “Advocating for Pasteurized Donor Human Milk: The Journey for
Medicaid Reimbursement in New York State”
4. A manuscript titled “The Case for the Inclusion of Pasteurized Donor Human Milk
into a State’s Medicaid Reimbursement Structure”
The poster presentation at the 2018 International Congress on Human Milk Banking was
titled “Nurse Driven Advocacy: Medicaid Reimbursement for Pasteurized Donor Milk Provided
to Very Low Birthweight Neonates.” The poster articulated the need for evidence-based
advocacy tools to demonstrate the potential cost savings associated with PDHM.
The poster presentation at ISPOR was titled “The Case for the Inclusion of Human Milk
into the State’s Medicaid Reimbursement Structure: A Budget Impact Analysis.” The poster
described the fiscal impact to Georgia Medicaid following the implementation of reimbursement
policies for PDHM for VLBW neonates.
Both manuscripts were submitted to Advances in Neonatal Care, the official journal for
the National Association of Neonatal Nurses.
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Reflection
Working with Mr. Salcedo to create an evidence-based tool was an opportunity for me to
consolidate and demonstrate the objectives of a doctoral education (American Association of
Colleges of Nursing, 2006). My scholarship advocates for the elimination of cost barriers
associated with PDHM. My work reflects an ability to conceptualize an identified health
disparity within an organizational or system construct (i.e., the state) and proposes that policy
development is an appropriate method to ensure quality improvement for a vulnerable
population. Creating the cost calculator required me to apply analytic methods to appraise
evidence as I participated in a collaboration which sought to improve health outcomes for
Georgia’s VLBW neonatal population. Working in an interdisciplinary team resulted in a tool
that surpasses anything either Mr. Salcedo or myself could have formed had we worked within
our respected areas of expertise. Perhaps this project will serve to motivate future students to
create interdisciplinary projects aligned with the mission statement of Yale School of Nursing:
“better health for all people.”

Medicaid Reimbursement

46
References

Abdullah, A. F., Zhang, Y., Camp, M., Mukherjee, D., Gabre-Kidan, A., Colombani, P. M., &
Chang, D. C. (2010). Necrotizing enterocolitis in 20 822 infants: Analysis of medical and
surgical treatments. Clinical Pediatrics, 49, 166-171. doi:10.1177/0009922809349161
Ahrabi, A. F., & Schanler, R. J. (2013). Human milk is the only milk for premies in the NICU!
Early Human Development, 89, s51-S53. doi:10.1016/j.earlhumdev.2013.08.006
Aly, A. A. (1996) The wet nurse: A study in ancient medicine and Greek papyri. Vesalius 2(2),
86-97. Retrieved from
http://www.biusante.parisdescartes.fr/ishm/vesalius/vesx1996x02x02x086x097.pdf
American Academy of Pediatrics: Provisional Section on Breastfeeding. (2001). WIC Program.
Pediatrics, 108, 1216-1217. Retrieved from
http://pediatrics.aappublications.org/content/108/5/1216
American Academy of Pediatrics. (2012). Breastfeeding and the use of human milk. Pediatrics,
129, e827–e841. doi:10.1542/peds.2011-3552
American Academy of Pediatrics. (2016). Donor human milk for the high-risk infant:
preparation, safety, and usage options in the United States. Pediatrics 139, e20163440 e20163440. doi:10.1542/peds.2016-3440
American Association of Colleges of Nursing. (2006). The essentials of doctoral education for
advanced nursing practice. Washington D.C. Retrieved from
https://www.pncb.org/sites/default/files/2017-02/Essentials_of_DNP_Education.pdf
Arnold, L. D. W. (2002). The cost-effectiveness of using banked donor milk in the neonatal
intensive care unit: Prevention of necrotizing enterocolitis. Journal of Human Lactation,
18, 172-177. doi:10.1177/089033440201800210

Medicaid Reimbursement

47

Arnold, L. D. W. (2010). Human milk in the NICU: Policy into practice. Sudbury, MA: Jones
and Bartlett Publishers.
Assad, A., Elliott, M., & Abraham, J. (2016). Decreased cost and improved feeding tolerance in
VLBW infants fed an exclusive human milk diet. Journal of Perinatology, 36, 216-220.
doi:10.1038/jp.2015.168
Ballard, O., & Morrow, A. L. (2013). Human milk composition: nutrients and bioactive factors.
Pediatric Clinics of North America, 60, 49-74. doi:10.1016/j.pcl.2012.10.002
Bashan, B. & Holsblat, R. (2017). Reflective journals as a research tool: The case of student
teachers’ development of teamwork. Cogent Education, 4.
doi:10.1080/2331186X.2017.1374234
Bertino, E., Giuliani, F., Baricco, M., Di Nicola, P., Peila, C., Vassia, C., … Coscia, A. (2013).
Benefits of donor milk in the feeding of preterm infants. Early Human Development, 89,
S3–S6. doi:10.1016/j.earlhumdev.2013.07.008
Bisquera, J. A., Cooper, T. R., & Berseth, C. L. (2002). Impact of necrotizing enterocolitis on
length of stay and hospital charges in very low birth weight infants. Pediatrics, 109, 423428. doi:10.1542/peds.109.3.423
Boundy, E. O., Perrine, C. G., Nelson, J. M., & Hamner, H. C. (2017). Disparities in hospitalreported breast milk use in neonatal intensive care units – United States. Morbidity,
Mortality Weekly Report, 66, 1313-1317. doi:10.15585/mmwr.mm6648a1.
Callen, J., & Pinelli, J. (2005). A review of the literature examining the benefits and challenges,
incidence and duration, and barriers to breastfeeding preterm infants. Advances in Neonatal
Care, 5, 72–88. doi:10.1016/j.adnc.2004.12.003

Medicaid Reimbursement

48

Carroll, K., & Herrmann, K. R. (2013). The cost of using donor human milk in the NICU to
achieve exclusively human milk feeding through 32 weeks postmenstrual age.
Breastfeeding Medicine, 8, 286-290. doi:10.1089/bfm.2012.0068
Centers for Medicare & Medicaid Services. (2012). Medicaid coverage of lactation services
[Coverage Update]. Retrieved from Department of Health and Human Services:
https://www.medicaid.gov/medicaid/quality-ofcare/downloads/lactation_services_issuebrief_01102012.pdf
Centers for Medicare & Medicaid Services. (2013). HCPCS level II coding process & criteria
[Policy update]. Retrieved from
https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/Downloads/HCPCSLevelII
CodingProcedures7-2011.pdf
Chabra, S. (2015). International classification of diseases, 10th Revision, coding for prematurity:
need for standardized nomenclature. The Health Care Manager, 34, 123-127.
doi:10.1097/HCM.0000000000000053
Coffman, J., & Beer, T. (2015). The advocacy strategy framework: A good for articulating an
advocacy theory of change. Retrieved from Center for Evaluation Innovation:
http://www.evaluationinnovation.org/sites/default/files/Adocacy%20Strategy%20Frame
work.pdf
Cristofalo, E. A., Schanler, R. J., Blanco, C. L., Sullivan, S., Trawoeger, R., KiechlKohlendorfer, U., ... Abrams , S. (2013). Randomized trial of exclusive human milk
versus preterm formula diets in extremely premature infants. The Journal of Pediatrics,
163, 1592-1595. doi:10.1016/j.jpeds.2013.07.011

Medicaid Reimbursement

49

Davies, D. P. (1977). Adequacy of expressed breast milk for early growth of preterm infants.
Archives of Disease in Childhood, 52, 296-301. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1544654/
Davis, W. H. (1913). Statistical comparison of the mortality of breast-fed and bottle-fed infants.
The American Journal of Diseases of Children, V(3), 234-247.
doi:10.1001/archpedi.1913.04100270040003
Dixon, J. (2017). Evaluation: part 2. Formative and process evaluation. Outcome evaluation –
pre and posttest, time series. [PowerPoint slides].
Eaton, S., Rees, C. M., & Hall, N. J. (2016). Current research in necrotizing enterocolitis. Early
Human Development, 97, 33-39. doi:10.1016/j.earlhumdev.2016.01.013
Falen, T. M., & Liberman, A. (2009). Coding, reimbursement, and managed care. The Health
Care Manager, 28, 194-208. doi:10.1097/HCM.0b013e3181b3f1ac
Fitzgibbons, S. C., Ching, Y., Yu, D., Carpenter, J., Kenny, M., Weldon, C., . . . Jaksic, T.
(2009). Mortality of necrotizing enterocolitis expressed by birth weight categories.
Journal of Pediatric Surgery, 44, 1072-1076. doi:10.1016/j.jpedsurg.2009.02.013
Food and Drug Administration. (2017). National Drug Code Directory [Policy directory].
Retrieved from https://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm
Food and Drug Administration. (2016). Use of donor human milk. Retrieved from Science and
Research Topics Pediatrics:
https://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm
235203.htm

Medicaid Reimbursement

50

Frost, B. L., Modi, B. P., Jaksic, T., & Caplan, M. S. (2016). New medical and surgical insights
into neonatal necrotizing enterocolitis: A review. JAMA Pediatrics,
doi:10.1001/jamapediatrics.2016.2708
Fullerton, B. S., Hong, C. R., Velazco, C. S., Mercier, C. E., Morrow, K. A., Edwards, E. M., . . .
Jaksic, T. (2017). Severe neurodevelopmental disability and healthcare needs among
survivors of medical and surgical necrotizing enterocolitis: A prospective cohort study.
Journal of Pediatric Surgery, doi:S0022-3468(17)30651-6 [pii]
Ganapathy, V., Hay, J. W., & Kim, J. H. (2012). Costs of Necrotizing Enterocolitis and CostEffectiveness of Exclusively Human Milk-Based Products in Feeding Extremely
Premature Infants. Breastfeeding Medicine, 7(1), 29-37. doi:10.1089/bfm.2011.0002
Georgia Budget & Policy Institute. (2017). Georgia health budget primer for state fiscal year
2018 [Annual report]. Retrieved from https://gbpi.org/wpcontent/uploads/2017/07/Georgia-Budget-Primer-2018-1.pdf
Georgia Department of Community Health. (2012, July 1). Medicaid state plan. Retrieved
December 11, 2016, from https://dch.georgia.gov/medicaid-state-plan
Georgia Department of Community Health. (2015, July 7). Medicaid. Retrieved December 12,
2016, from Medicaid organizational structure, https://dch.georgia.gov/medicaid
Georgia Department of Community Health. (2016). Medicaid FAQs. Retreived October 30,
2017, from Medicaid FAQs, https://dch.georgia.gov/medicaid-faqs#eligibility
Georgia Department of Community Health. (2017, August 29). Blake T. Fulenwider named new
Deputy Commissioner, Georgia Medicaid Chief [Press release]. Retrieved from
https://dch.georgia.gov/press-releases/2017-08-29/blake-t-fulenwider-named-newdeputy-commissioner-georgia-medicaid-chief

Medicaid Reimbursement

51

Georgia Department of Public Health. (2014). Reducing infant mortality in Georgia. Retrieved
from
https://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/Infant%20Mort
ality%20Report%20FINAL%207%20single.pdf
Georgia Department of Public Health. (2017). WIC formula resources. Retrieved from
https://dph.georgia.gov/wic-formula-resources
Georgia Department of Public Health; OASIS [Database record]. (2016). Retrieved from Online
Analytical Statistical Information System.
https://oasis.state.ga.us/oasis/webquery/qryBirth.aspx
Georgia Families Medicaid & PeachCare for Kids. (2017). Member Handbook [Consumer
brochure]. Retrieved from
https://www.pshpgeorgia.com/content/dam/centene/peachstate/pdfs/PSHPGA_MbrHandbk_v3-30-10_508.pdf
Georgia WIC. (2017). Georgia WIC Clinic and Authorized Stores [Data file]. Retrieved from
https://sendss.state.ga.us/sendss/!wicclinic.SCREEN
Gross, S. J. (1983). Growth and biochemical response of preterm infants fed human milk or
modified infant formula. The New England Journal of Medicine, 308, 237-241.
doi:10.1056/NEJM198302033080501
Gupta, A., & Paria, A. (2016). Etiology and medical management of NEC. Early Human
Development, 97, 17-23. doi:10.1016/j.earlhumdev.2016.03.008
Hair, A. H., Peluso, A. M., Hawthorne, K. M., Perez, J., Smith, D. P., Khan, J. Y., ... Abrams , S.
A. (2016). Beyond necrotizing enterocolitis prevention: Improving outcomes with an

Medicaid Reimbursement

52

exclusive human milk–based diet. Breastfeeding Medicine, 11, 70-74.
doi:10.1089/bfm.2015.0134
Harding, J. J. (2015). Billing for neonatal critical care. Neonatology Today, 10, 7. Retrieved from
http://www.neonatologytoday.net/newsletters/nt-jan15.pdf
Hoefer, R. (2016). Advocacy practice for social justice (3rd ed.). Chicago, IL: Lyceum Books,
Inc.
Human Milk Banking Association of North America (2017). Nonprofit milk banks collaborate in
North Texas to help fragile babies [Press Release]. Retrieved
https://www.hmbana.org/sites/default/files/images/MILK%20BANK%20SYMPOSIUM
%20PRESS%20RELEASE.pdf
Jacobs, J., Kamitsuka, M., Clark, R., Kelleher, A. S., & Spitzer, A. R. (2015). Etiologies of
NICU deaths. Pediatrics, 135, 775-777. doi:10.1542/peds.2014-4207
Johnson, T. J., Patel, A. L., Bigger, H. R., Engstrom, J. L., & Meier, P. P. (2015). Cost savings of
human milk as a strategy to reduce the incidence of necrotizing enterocolitis in very low
birth weight infants. Neonatology, 107, 271-276. doi:10.1159/000370058
Johnson, T. J., Patel, A. L., Jegier, B. J., Engstrom, J. L., & Meier, P. P. (2013). Cost of
morbidities in very low birth weight infants. The Journal of Pediatrics, 162, 243-49.e1.
doi:10.1016/j.jpeds.2012.07.013
Jones, F. (2003). History of North American donor milk banking: One hundred years of progress.
Journal of Human Lactation, 19, 313-318. doi:10.1177/0890334403255857
Kaiser Family Foundation. (2017). Births financed by Medicaid. Retrieved from
https://www.kff.org/medicaid/state-indicator/births-financed-bymedicaid/?currentTimeframe=0&selectedRows=%7B%22states%22:%7B%22georgia%2

Medicaid Reimbursement

53

2:%7B%7D%7D%7D&sortModel=%7B%22colId%22:%22Time%20Period%20Reporte
d%22,%22sort%22:%22desc%22%7D
King, V., Thielke, A., Carson, S., Leof, A., Dion, D., Holup, J., & Harrod, C. (2017). Donor
human milk for low birthweight infants: Effectiveness and policies. Portland, OR: Center
for Evidence-based Policy, Oregon Health & Science University.
https://www.health.ny.gov/health_care/medicaid/ebbrac/docs/2017-0613_donor_human_milk.pdf
March of Dimes. (2016). CHIP coverage for pregnant women [Policy brief]. Retrieved from
https://www.marchofdimes.org/MOD-CHIP-Coverage-for-Pregnant-Women-UpdatedMay-2016.pdf
March of Dimes. (2016). Medicaid coverage of births in Georgia. Retrieved December 1, 2016,
from PeriStats,
http://www.marchofdimes.org/Peristats/ViewSubtopic.aspx?reg=13&top=11&stop=154
&lev=1&slev=4&obj=1
Medicaid and CHIP Payment and Access Commission. (2017). Medicaid 101. Retrieved from
https://www.macpac.gov/medicaid-101/
Miller, A. (2012, March 5). Atlanta’s Grady hospital chief sees major threat in Medicaid cuts.
Kaiser Health News. Retrieved from http://khn.org/news/grady-hospital-ceo-haupertmedicaid-cuts
Miller, L. B. (2017). Review of journaling as a teaching and learning strategy. Teaching and
Learning in Nursing, 12, 39-42. doi:10.1016/j.teln.2016.10.004
Miracle, J. D., Szucs, A. K., Torke, M. A., & Helft, R. P. (2011). Contemporary ethical issues in
human milk-banking in the United States. Pediatrics, 128(6).

Medicaid Reimbursement

54

doi:10.1542/peds.2010-2040
National Association of Neonatal Nurses. (2016). Reimbursement for donor human milk for
preterm infants [Issue Brief]. Retrieved from
http://nann.org/uploads/Advocacy_Fact_Sheets/2016_Donor_Breast_Milk.pdf
National Association of WIC Directors (2000, March 1). Human Milk Banks Used by WIC
Programs. Monday Morning Report
Neu, J., & Walker, W. A. (2011). Necrotizing enterocolitis. The New England Journal of
Medicine, 364, 255-264. doi:10.1056/NEJMra1005408
Obladen, M. (2012). Regulated wet nursing: Managed care or organized crime? Neonatology,
102, 222-228. Retrieved from doi: 10.1159/000339732
Papillon, S., Castle, S. L., Gayer, C. P., & Ford, H. R. (2013). Necrotizing enterocolitis:
Contemporary management and outcomes. Advances in Pediatrics, 60, 263-279.
doi:10.1016/j.yapd.2013.04.011
Parker, M. G., Barrero-Castillero, A., Corwin, B. K., Philipp, B., Merewood, A., Kavanagh, P.
L., ... Wang, C. J. (2013). Pasteurized human donor milk use among US level 3 neonatal
intensive care units. Journal of Human Lactation, 29, 381-389.
doi:10.1177/0890334413492909
Patient Protection and Affordable Care Act, 42 U.S.C. § 18001 et seq. (2010).
Porter, J. (2017) Why you should make time for self-reflection (even if you hate doing it.
Managing Yourself. Boston, Mass: Harvard Business Publishing. Retrieved from:
https://hbr.org/2017/03/why-you-should-make-time-for-self-reflection-even-if-you-hatedoing-it

Medicaid Reimbursement

55

Prince, A., & Groh-Wargo, S. (2013). Nutrition management for the promotion of growth in very
low birth weight premature infants. Nutrition in Clinical Practice, 28, 659-668.
doi:10.1177/0884533613506752
Quigley, M., & McGuire, W. (2014) Formula versus donor breast milk for feeding preterm or
low birth weight infants. Cochrane Database of Systematic Reviews, (4).
doi:10.1002/14651858.CD002971.pub3
Raterink, G. (2016). Reflective journaling for critical thinking development in advanced practice
registered nurses. Journal of Nursing Education, 55, 101-104.
doi:10.3928/01484834-20160114-08
Schultz, K., Soltesz, G., & Mestyan, J. (1980). The metabolic consequences of human milk and
formula feeding in premature infants. Acta Paediatrica Scandinavica, 69, 647-652.
doi:10.1111/j.1651-2227.1980.tb07337.x
Sedgwick, J. P. (1917). Establishment, maintenance, and reinstitution of breast feeding. In (Ed.),
Transactions of the section on diseases (pp. 17-22). Chicago, IL: American Medical
Association Press. (Reprinted from The Journal of the American Medical Association,
1917)
Schön, D.A. (1983). The reflective practitioner: How professionals think in action. New York,
NY: Basic Books.
Special Supplemental Nutrition Program for Women, Infants and Children (WIC): Revisions in
the WIC food packages, 79:42 Federal Register § 12274-12300 (2014).
http://www.federalregister.com/Browse/Document/usa/na/fr/2014/3/4/2014-04105).

Medicaid Reimbursement

56

Srivastava, A., & Thomson, S.B. (2009). Framework analysis: A qualitative methodology for
applied policy research. Journal of Administration and Governance.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2760705
Stetler, C. B., Legro, M. W., Wallace, C. M., Bowman, C. Guihan, M., Hagedorn, H…..Smith J.
L. (2006). The role of formative evaluation in implementation research and the QUERI
experience. Journal of General Internal Medicine, 21, S1-8.
doi:10.1111/j.1525-1497.2006.00355.x
Stevens, E., E., Patrick, T. E., & Pickler, R. (2009). A history of infant feeding. The Journal of
Perinatal Education 18(2): 32-39. Retrieved from: doi:10.1624/105812409X426314
Sullivan, S., Schanler, R. J., Kim, J. H., Patel, A. L., Trawöger, R., Kiechl-Kohlendorfer, U.,...
Lucas, A. (2010). An exclusively human milk-based diet is associated with a lower rate
of necrotizing enterocolitis than a diet of human milk and bovine milk-based products.
The Journal of Pediatrics, 156, 562-567. doi:10.1016/j.jpeds.2009.10.040
Teitelbaum, J. B., & Wilensky, S. E. (2017). Essentials of health law and policy (3rd ed.). Jones
and Bartlett.
Thompson, A. M., & Bizzarro, M. J. (2008). Necrotizing enterocolitis in newborns:
pathogenesis, prevention and management. Drugs, 68, 1227-1238. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/18547133
Thorley, V., & Sioda, T. (2016). Selection criteria for wet-nurses: Ancient recommendations that
survived across time. Breastfeeding Review, 24, 13-24. Retrieved from
https://www.ncbi.nlm.nih.gov/pubmed/?term=Selection+criteria+for+wetnurses%3A+Ancient+recommendations+that+survived+across+time.

Medicaid Reimbursement

57

U.S. Department of Health and Human Services. (2011). The Surgeon General's call to action to
support breastfeeding
(https://www.surgeongeneral.gov/library/calls/breastfeeding/calltoactiontosupportbreastfe
eding.pdf). Washington, DC: Government Printing Office.
United States Department of Agriculture Food and Nutrition Services. (2017). 2017 WIC grant
levels [Data file]. Retrieved from https://www.fns.usda.gov/wic/wic-funding-andprogram-data
United States Department of Agriculture Food and Nutrition Services. (2016). About WICWIC's Mission. Retrieved from https://www.fns.usda.gov/wic/about-wic-wics-mission
Vermont Oxford Database. (2016, January). Nightingale report: necrotizing enterocolitis rates in
2015. Retrieved from
https://login.vtoxford.org/login.aspx?ReturnUrl=https%3a%2f%2fnightingale.vtoxford.or
g%2f
Wachino, V., Schneider, A., & Rousseau, D. (2004). Financing the Medicaid program: The
many roles of federal and state matching funds
kaiserfamilyfoundation.files.wordpress.com/2013/01/financing-the-medicaid-programthe-many-roles-of-federal-and-state-matching-funds-policy-brief.pdf
Warrington Earle, C. (1888, August 4). Infant feeding. Journal of the American Medical
Association, XI(5), 150-155. doi:10.1001/jama.1888.02400570006001a
Watkins, S. R. (2000, March 1). WIC to hold use of banked human breast milk.
World Health Organization. (2011). Optimal feeding of low birth weight infants in low-and
middle-income countries. Retrieved from
http://www.who.int/maternal_child_adolescent/documents/9789241548366.pdf?ua=1

Medicaid Reimbursement

58
Footnotes

1.

Interviews of key informants will bring depth to the enacted state policies. The

interviews will be structured to provide a qualitative description of the implementation of
reimbursement/logistic policies. In addition to a description of policy implementation, the
interviewee will have the opportunity to describe the advocacy efforts utilized to achieve state
reimbursement. Information will be utilized to inform advocacy efforts in Georgia.
2.

In addition to the identified educational material, efforts are currently underway to

collaborate with experts in pharmacoeconomic data. The collaboration will produce a
deliverable. The deliverable would be an “Excel Spread Sheet calculator” utilized for
demonstrating net savings for Georgia Medicaid. Because the incidence of NEC in the VLBW
population fluctuates between 5% and 10% (Neu & Walker, 2011; Thompson & Bizzarro, 2008),
a flexible pharmacogenomics tool (i.e., a calculator) is ideal. Due to the potential
unforeseen/unknown complications of creating a Georgia specific tool the scholarly project is
unable to guarantee production of the deliverable within the current time frame. The projects
faculty advisor, Lisa Summers, DrPH, FACNM will be kept up to date with the collaborative
efforts.
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Tables

Table 1
Overview of PDHM Reimbursement
State &
Year of
Enactment
California
(1988)

Policy Details

Donor milk is used for patients in the NICU or for
qualified infants who meet a set criteria; both inpatient and
outpatient.

Method of Advocacy

Legislative Process

Utilizes HCPCS code T2101 for outpatient. Unclear how
inpatient is billed.
Rate of Reimbursement is $2.94 per once for donor milk.
Milk must be obtained via a HBANA milk bank operating
within California.
District of
Columbia
(2014)

No Reimbursement for lactoengineered products.
Medical necessity must be documented every 180 days
following a failed feeding trial of traditional nutritional
strategies, unless the patient is deemed too fragile.

Unclear

Reimbursement is only available to outpatients
Utilizes HCPCS code T2101 for outpatient.
Rate of Reimbursement is $3.30 per once for donor milk.
Milk must be obtained by a HBANA or another milk back
that has meet appropriate standards described by the
Department of Health Care Finance.
Kansas
(2016)

No Reimbursement for lactoengineered products.
Reimbursement is available to infants under three months
of age and hospitalized.
Reimbursement is only available to inpatients.
Authorization from the Kansas Department of Health &
Environment is required for reimbursement – however
reimbursement provides retroactive coverage to PDHM
provided prior to authorization approval
PDHM must be obtained by a Milkbank that meets the
standards outlined by KDHE
No Reimbursement for lactoengineered products.

Legislative Process
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(2015)
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Reimbursement is available to infants under three months
of age and hospitalized.

Legislative Process

Reimbursement is only available to inpatients.
Authorization is required for reimbursement. Unclear who
authorizes (possibly the Department of Social Services).
PDHM must be obtained by a Milkbank that meets the
standards of the “departments” guidelines.
No Reimbursement for lactoengineered products.
New York
(2017)

Donor milk is reimbursed to patients in the NICU or for
qualified infants who meet a set criteria.

Legislative Process –
Failed

Utilizes HCPCS code T2101 for outpatient. Unclear how
inpatient is billed.

Regulatory Policy
Change – Successful

No Reimbursement for lactoengineered products.
Texas
(2008;
Outpatients
& 2016;
Inpatients)

Reimbursement is available to inpatients (6 months and
younger – no prior authorization is required), and
outpatients (20 years and less with appropriate
documentation; authorization is required every 6 months).

Legislative Process

Inpatients: Bill Revenue Code 220 (special charges) along
with HCPCS code T2101. Outpatients: Procedure Code
B9998.
Inpatients: Rate of Reimbursement is $2.00 per once.
Outpatients: Reimbursed at a fee determined by the Texas
Health and Human Services or ‘manual pricing’
Milk must be obtained via a Texas Medicaid-enrolled milk
bank.
No Reimbursement for lactoengineered products.

Utah

Donor milk reimbursed is only available for the outpatient
setting for qualified infants 11 months or less.

Legislative Process

Milk must be obtained via a HBANA milk and enrolled as
a Utah Medicaid provider or from a distributor that meets
the requirements that may be adopted by the Utah
Medicaid program.
Prior authorization must be obtained, and resubmitted
every 180 days.
No Reimbursement for lactoengineered products.

* Table adapted from King et al. (2017)
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Table 2
Access to PDHM in Georgia Hospitals that Deliver Care to Neonates
Region

Hospital

PDHM Access

Albany

Colquitt Regional Medical Center

No

Albany
Albany
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta

Phoebe Putney Memorial Hospital
South Georgia Medical Center
Cherokee Northside Hospital
DeKalb Medical
Eastside Medical Center
Emory John’s Creek Hospital
Emory University Hospital Midtown

Yes
No
No
Yes
No
Yes
Yes

Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta
Atlanta

Grady Memorial Hospital
Gwinnett Hospital
Northeast Georgia Medical Center
Northside Hospital
Piedmont Atlanta Hospital
Piedmont Fayette Hospital
Piedmont Henry Hospital
Piedmont Mountainside Hospital
Piedmont Newton Hospital
Rockdale Medical Center
South Regional Medical Center
WellStar Cobb Hospital
WellStar Douglas Hospital

No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
Yes
No

Atlanta
Atlanta
Augusta
Augusta
Augusta
Augusta
Augusta
Augusta
Augusta
Augusta
Columbus

WellStar Kennestone Hospital
WellStar Spalding Regional Hospital
Athens Regional Medical Center
Doctors Hospital
Emanueal Medical Center
Georgia Regents University
St. Mary’s Hospital of Athens
Trinity Hospital
University Hospital
Walton Regional Medical Center
Martin Army Community Hospital

Yes
No
Yes
Yes
No
Yes
No
No
Yes
No
No

Columbus
Columbus
Columbus
Columbus
Columbus
Columbus

Piedmont Newnan Hospital
Spalding Regional Hospital
Sumter Regional Hospital
Tanner Medical Center – Carrollton
Tanner Medical Center – Villa Rica
The Medical Center – Columbus

Yes
No
No
No
No
No
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Columbus
Columbus
Macon
Macon

Upston Regional Medical Center
West Georgia Medical Center
Coliseum Medical Center
Crisp Regional Hospital

No
No
No
No

Macon
Macon
Macon
Macon
Macon
Macon
Macon
Savannah
Savannah
Savannah
Savannah
Savannah
Savannah
Savannah

No
No
No
No
No
Yes
No
No
No
No
No
No
No
Yes

Savannah
Savannah

Dodge County Hospital
Fairview Park Hospital
Houston Medical Center
Oconee Regional Medical Center
Taylor Regional Hospital
The Medical Center of Central Georgia
Tift Regional Medical Center
Bacon County Hospital
Coffee Regional Medical Center
East Georgia Regional Medical Center
Liberty Regional Medical Center
Mayo Clinical Health System
Meadows Regional Medical Center
Memorial Health University Medical
Center
Southeast Georgia Healthcare System:
Brunswick Campus
Southeast Georgia Healthcare System:
Camden Campus
St. Joseph’s/Candler Health System
Wayne Memorial Hospital

Savannah

Winn Army Community Hospital

No

Savannah
Savannah

No
No
No
No

Total Hospitals: 61 Hospitals in the State of Georgia deliver care for neonates.
Hospitals that have access to PDHM: 20 or 33%
Hospitals that do not have access to PDHM:41 or 67%
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Table 3
Cost-Effectiveness (Reported by Ganapathy et al., 2012)

a
b

Category of Cost

Formula Utilized

SBBNR

Total costs for
supplements used per
OSHPD entry

a

([median quantity of
$195
supplement used x unit cost of
supplement] + [median quantity
of supplement used when MBM
was not available x unity cost of
supplement]) = C1

$10,321

Average baseline
hospitalization cost
per OSHPD

(1 x mean baseline costs
estimate of a EP neonate
without NEC) b

$207,378

$207,378

Expected incremental
costs for OSHPD
entry with a NEC dx.

(p1a x mean adjusted
incremental costs of NEC) = C3

$11,798

$4,290

Expended
incremental cost for
OSHPD entry who
required surgery to
address the NEC dx.

(p2a x [mean adjusted
incremental costs of surgical
NEC-mean adjusted
incremental costs of medical
NEC]) = C4

$12,583

$1,798

Total expected NICU
costs per OSHPD
entry

TC = C1+C2+C3+C4

$231,954

$223,787

Net savings in
hospital costs per EP
infant owing to
EHMD over SBBNR

TCBFNR - TCEHMD

$8,167

Favors
EHMD

= Data comes from Sullivan et al. (2010); mirrors constraints 3 – 6.
= Data comes from OSHPD benchmark

* Table Adapted from Ganapathy et al. (2012)

EHMD
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Table 4
Audience Members to Engage in Georgia
Members of the
Public to Engage

Influencers to Engage
Georgians for a Healthy
Future

Parents with NICU
experience

Healthy Mothers, Healthy
Babies Coalition of
Georgia

Decision Makers to Engage
Medicaid Directors
The Department of Community
Health
The Department of Public Health

Healthcare Professionals
who are stakeholders in
neonatal outcomes
Child advocates who are
stakeholders in neonatal
outcomes

Babies Can’t Wait
American Academy of
Pediatrics – Georgia
Chapter
National Association of
Neonatal Nurses –
Georgia Chapter
Georgia Health Policy
Center
Georgia Perinatal Quality
Collaboration
Georgia Hospital
Association

Representatives from the Governor’s
Budget Office
Elected officials who have personal
experience with the NICU
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Table 5
Base Case Costs Without Policy
Time Frame
Interval
Short-term
6 Months
12 Months
24 Months
36 Months

Costs
Total
$70.15 M
$76.25 M
$79.21 M
$83.77 M
$85.98 M

Per-Patient
$102,359
$111,271
$115,585
$122,237
$125,459

Table 6
Base Case Costs Following Policy Adoption
Time Frame
Interval
Short-term
6 Months
12 Months
24 Months
36 Months

Savings
Total
$65.35 M
$70.59 M
$73.11 M
$77.58 M
$79.87 M

Per-Patient
$95,358
$103,012
$106,688
$113,200
$116,554

Table 7
Base Case Cost Savings Following Policy Adoption
Time Frame
Interval
Short-term
6 Months
12 Months
24 Months
36 Months

Total
$4,797,444
$5,659,909
$6,097,070
$6,193,549
$6,102,569

Savings
Per-Patient
$7,001
$8,259
$8,897
$9,038
$8,905
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Table 8
Probabilistic Sensitivity Analysis Cost Savings Following Policy Adoption (Monte Carlo 10,000)

Time Frame
Short-term
6 Months
12 Months
24 Months
36 Months

Average Savings
Total
Per-Patient
$4,805,027
$7,012
$5,668,904
$8,272
$6,106,867
$8,911
$6,193,023
$9,037
$6,130,930
$8,946

Cost Savings Iterations
Number
Percent
8,980
89.8%
9,018
90.2%
9,017
90.2%
8,916
89.2%
8,852
88.5%

Total Savings
Per-patient
Lower
Upper
Lower
Upper
Bounds
Bounds
Bounds
Bounds
Time Frame
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Short-term
$4,712,792
$4,899,964
$6,877
$7,150
6 Months
$5,555,760
$5,787,286
$8,107
$8,445
12 Months
$5,960,295
$6,252,544
$8,697
$9,124
24 Months
$6,046,431
$6,339,398
$8,823
$9,251
36 Months
$5,982,686
$6,273,311
$8,730
$9,154
Nonparametric 95% confidence intervals (basic empirical) obtained using bootstrapped samples
(R=9,999)
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Figures

* From Coffman & Beer (2015) The advocacy strategy framework: a tool for articulating and
advocacy theory of change.
Figure 1. Pictorial representation of the ASF. *

Medicaid Reimbursement

* From Coffman & Beer (2015) The advocacy strategy framework: a tool for articulating and
advocacy theory of change
Figure 2. Examples of advocacy tactics. *
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Community Mobilization

Coalition Building

Will

Awareness

Regulatory Feedback

Champion
Development

Community Organizing

Communications and
Messaging

Public Education

Influencer Education

Policy Maker
Education

Public

Influencers

Decision Makers

Figure 3. Georgia advocacy strategy within the ASF.
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VARIABLE NAME
NEC_6MO
NEC_II_COST
NEC_I_COST
CONTROL_6MO
SNEC_6MO
CONTROL_24MO
CONTROL_36MO
NEC_24MO
SNEC_24MO
NEC_36MO
SNEC_36MO
SNEC_SURV_6MO
NEC_II_SNEC
DISCOUNT
DONOR_MILK_COST
MNEC_SURV_6MO
FORMULA_MILK_COST
CONT_SURV_6MO
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Cost of healthcare utilization during the first 6 months of life after initial
hospitalization in infants diagnosed with medical NEC
Cost of initial hospitalization in neonates who have been diagnosed with NEC and
are at risk for developing surgical NEC
Cost of initial hospitalization if neonates who have been diagnosed with NEC
Cost of healthcare unitization during the first 6 months of life after VLBW initial
hospitalization but without NEC
Cost of healthcare utilization during the first 6 months of life in infants with a
diagnosis of surgical NEC after initial hospitalization
Cost of healthcare utilization during the first 24 months of life after VLBW initial
hospitalization but without NEC
Cost of healthcare utilization during the first 36 months of life without PHHM
reimbursement policies
Cost of healthcare utilization during the first 24 months of life in infants with a
diagnosis of NEC
Cost of healthcare utilization during the first 24 months of life in infants with a
diagnosis of surgical NEC
Cost of healthcare utilization during the first 36 months of life in infants with a
diagnosis of NEC
Cost of healthcare utilization during the first 36 months of life in infants with a
diagnosis of surgical NEC
Survival at 6 months with infants who had a diagnosis of surgical NEC
Probability of a neonate with NEC who will require a surgical intervention
Cost of PDHM for the VLBW neonate while at risk for NEC
Survival at 6 months with infants who had a diagnosis of NEC who did not require
surgery
Cost of formula for the VLBW neonate while at risk for NEC
Probability of survival at 6 months of life without PDHM reimbursement policies

VARIABLE*

DISTRIBUTION

SOURCE

NEC_6MO

Gamma

Assumption using Ganapathy et al. (2013)

NEC_II_COST
NEC_I_COST
CONTROL_6MO
SNEC_6MO
CONTROL_24MO
CONTROL_36MO
NEC_24MO
SNEC_24MO
NEC_36MO
SNEC_36MO
SNEC_SURV_6MO
NEC_II_SNEC
DISCOUNT
DONOR_MILK_COST
MNEC_SURV_6MO
FORMULA_MILK_COST
CONT_SURV_6MO

Gamma
Gamma
Gamma
Gamma
Gamma
Gamma
Gamma
Gamma
Gamma
Gamma
Beta
Beta
Uniform
Beta
Beta

Georgia Medicaid Data
Georgia Medicaid Data
Ganapathy et al. (2013)
Assumption using Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Ganapathy et al. (2013)
Holman et al. (2006)
Commercial Data
Ganapathy et al. (2013)
Commercial Data
Ganapathy et al. (2013)
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costs adjusted to 2017 USD
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Figure 4. One-way deterministic sensitivity analysis, Tornado diagram, and variable limits.
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Policy Search
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Policy Matrix
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Appendix C
Advocacy Field Notes
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Appendix D

Formative Evaluation Documentation Plan
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Appendix E
Reflective Journal Template
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Appendix F

Peer Reviewed Clinical Benefits Used to
Justify Intervetion of PDH M

Agency for Healthcare Research and Quality
(AHRQ)

ECRI Institute. AHRQ Healthcare Horizon Scanning
System Potential High Impact Interventions: Priority
Area 12: Pregnancy including Preterm Birth.
(Prepared by ECRI Institute under Contract No.
HHSA290201000006C.) Rockville, MD: Agency for
Healthcare Research and Quality. January 2012.
http://www.effectivehealthcare.ahrq.gov/reports/final.
cfm.

Jan-12

Yes. Most experts agreed that donor human milk banks have the
potential to significantly affect health disparities, with one research
expert stating that “ African Americans and socioeconomically
disadvantaged babies are most likely to be born prematurely. Not
having access to the health benefits of breast milk when their
Yes. Sullivan S, Schanler RJ, Kim JH, et mothers cannot provide it (whether for health or economic reasons)
al. An exclusively human milk-based diet
will put the babies at further long-term disadvantage if their
is associated with a lower rate of
development is impaired.” Another research expert stated, “ With the
necrotizing enterocolitis than a diet of
use of banked [human donor] milk, babies born to mothers with
human milk and bovine milk-based
HIV, drug addiction, or health problems who are unable to provide
products. J Pediatr 2010 Apr;156(4):562- breast milk for their infant will be able to receive the health benefits,
7.e1. PMID: 20036378
therefore reducing disparity.” But one research expert did not
believe in this intervention’ s ability to reduce health disparities,
citing the
fact that health insurance does not currently extend coverage for
human donor milk, therefore widening the barrier for the
economically disadvantaged" (pg. 4 - 5)

ECRI Institute. AHRQ Healthcare
Horizon Scanning System Potential
High- Impact Interventions: Priority
Area 12: Pregnancy, Including Preterm
Birth. (Prepared by ECRI Institute
under Contract No.
HHSA290201000006C.) Rockville,
MD: Agency for Healthcare Res

Dec-12

Primary Care Interventions
to Support Breastfeeding.
Updated Evidence Report
and Systematic Review for
the US Preventive Services
Task Force

10/25/16

Language to Address H ealth Disparities

Language to Address the
Language to address Logistic Policies (tracking,
Fiscal Benefits to the Language to Address Reimbursement Issues
distribution and monitioring)
H ealth Care System

No

Yes. " Diffusion has been limited in large
part by lack of awareness of the need and
inconsistent reimbursement mechanisms
and coverage policies. Hospitals may
consider donor human milk part of the
room and meal charge, include it in
pharmaceutical costs, pay for it out of
their unit’ s budget, or seek financial
Yes - however relates to the process of screening
support from private foundations.
donors, and the pasturization process. No mention of
Payment often depends on the diagnostic
systematic monitoring.
code assigned to the infant and on
prescribing-practitioner documentation.
The U.S. Centers for Medicare &
Medicaid Services has no national
coverage determination on donor breast
milk for premature infants and only one
State has mandated coverage." (pg. ES3)

No

No

No

12/8/17

Same Data/Report as in prior report that was published 1/12

No. The report mentions the decreased
assoication between PDHM and NEC,
sepsis and " other health outcomes"

Yes. Data from the 2015 Maternity Practices in Infant Nutrition and
Care (mPINC) survey of all U.S. maternity facilities, linked with
postal code–level race data from the U.S. Census, found that
hospitals in areas with higher percentages of black residents
reported lower percentages of infants in the neonatal intensive care
unit (NICU) routinely receiving mother’ s own breast milk (median =
72.0%) or banked donor breast milk (median = 5.0%) than did
hospitals in areas with lower percentages of black residents (median
= 80.0% and 10.0%, respectively).

No

3/22/18

The Use of Donor
Brest Milk

The Department of
Health and Human
Services

Agency for Healthcare
Ther Centers for Disease Control andResearch
Prevention
and(CDC)
Quality
(AHRQ)

Entity

Disparities in Hospital-Reported
Breast Milk Use in Neonatal
Intensive Care Units — United
States, 2015

Policy and/or
Year
Document Concerning
Publishe
PDH M (with
d
hyperlink)

Agency for Healthcare Research and
Quality
(AHRQ)

Results of Policy Search

No

No

No

No

Yes. Donor milk use might also be
affected by insurance reimbursement

No

Yes. The Report states that the role of systems to
distribute donor breast milk would be a worthwhile
cause for research

No

No
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Appendix G
Image of the Cost Calculator
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Appendix H
Reflective Journal Summarization
Formative Evaluation Summary for Aim Three

Aim Three Objective: Development of a calculation that will permit Medicaid directors to utilize state-specific data to demonstrate the
cost effectiveness of providing PDHM to VLBW neonates.

Assessment
Stage

Implementation Stage

Planning

Project
Stage

Form of
Evaluation

Guiding Question of the
Evaluation

Response from the
Evaluator

Evaluation Method

Result of the Evaluation

Developmental
Evaluation

"What Barriers do we
expect?"

Provided team with the results of
"That the intervention is
the data, changed the RCT
not satistically powerful
Table of Evidence source that was initally selected
enough to warrant a
as one of the constrants to power
policy change"
the cost calculator

ImplementationFocused
Evaluation

"What are we actually
doing?"

"What are we doing with
Reflective Journal
the data?"

ProgressFocuesed
Evaluation

"How is it working?"

Journaling allowed for an
opportunity to format question
"How is the team
Intradisiplinary
to be targeted. Provided a selfoperating?" "Are we
Reflective Journal
opportunity for self
meeting the objective?"
by C. Schmaltz
assessment/directed supplemental
reading

Interpretive
Evaluation

"Why is it happening
this way?"

Intradisiplinary

by C. Schmaltz

"Is this a functional
tool?"

Improved understanding in the
mathmatical framework which
the cost calculator operates from

Feedback from
Adjusted the interface/display of
Facility advisors at
the calculator to be more user
YSN, USC, and
friendly
policy experts
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Reflective Journal of the I nterdisciplinary Process

Primary Collaborators: C. Schmaltz & J. Salcedo Senior Team Members: J. Hay & L. Summers

Guiding Questions: " How is this working?" " How is the team operating? " Are we meeting the objective?"

7/6/18

6/8/18

6/1/18

4/19/18

3/1/18

Date

Meeting Type

Phone Call

Teleconference

Phone Call

Teleconference

Teleconference

Meeting Objective

Team Members
Present

Obtain agreement for
C. Schmaltz &
J. Hay to participate in
J. Hay
the project.

Meeting Summary

C. Schmaltz presented J. Hay with his
proposal of an evidence-based advocacy
tool (cost-calculator).

Solidify the project's
objective and identify
J. Hay described the process for the
C. Schmaltz, J.
the necessary the
creating of an effective cost-calculator, C.
Hay, & J.
methods required to
Schmaltz described his vision for the
Salcedo
create an evidencecompleted product
based advocacy tool.

Inform J. Salcedo on
the current state of
evidence supporting
the intervention.

C. Schmaltz &
J. Salcedo

Describe the statistical
methods required for C. Schmaltz &
an effective cost
J. Salcedo
calculator.

Meeting Outcome

J. Hay agreed to participate on the
This was the first step, and the request was articulated in a clear and
project; however, due to his time
succinct manner. Before approaching this project, YSN DNP curriculum
constraints, we will bring in J.
stressed the importance of moving away from silo thinking/action/research
Salcedo to be the primary
while encouraging our cohort to pursue interdisciplinary collaborative
economic collaborator during
projects.
project development.

Agreed upon the project's
objective.

Presented clinical evidence supporting the
Determined that evidence from the
provision of pasteurized donor human milk
presented literature review was
(PDHM), along with an epidemiological
sufficient to move forward with
summary of necrotizing enterocolitis
the project.
(NEC) and NEC clinical presentation.

Reviewed the description of various
statistical tools utilized in cost
effectiveness studies, and articulated the
identification of appropriate statistical
methods for our project.

Reflective Summarization

Methods of communication were agreed upon. A clear objective will assist
in targeting productive momentum towards the projects goal.

During this phone call, I was impressed with the depth of knowledge J.
Salcedo brought to the project. He referred to several studies that used a
similar decision tree. During our conversation, I knew I needed to
strengthen my knowledge of statistics in order to keep up and
appropriately contribute.

Agreed upon decision tree design
for an operational framework,
Due to the nature of this phone call it was important for me to speak
statistical evaluation method of
statistics with my collaborator. Had I not taken the time to review my
one-way deterministic sensitive
statistic course work I would have been more of a follower and less of a
analysis, and multivariate
collaborator. While Jonathan brings a level of statistical sophistication I
probabilistic sensitivity analysis don't poses, I was able to ask constructive feedback regarding variables and
(Monte Carlo Simulation
measured outcomes.
Method).

Deemed that data from Cochrane I am concerned that the effect measured (decrease NEC) from Quigley and
Articulate the data
Reviewed the clinical evidence that would
Review (Quigley & McGuire,
McGuire (2014) will underpower the effectiveness of the intervention
C. Schmaltz &
required to power the
serve to power the effectiveness of the
2014) was acceptable; however, C. (PDHM). My concern stems from their sample (which includes neonates
J. Salcedo
cost calculator.
intervention
Schmaltz will evaluate data
above 1500 grams), which is not reflective of the neonates most at risk for
reported from new publications.
developing NEC <1500 grams.

7/11/18

Phone Call

Teleconference

Meeting Objective

Team Members
Present

Solidify the
operational statistical C. Schmaltz &
process that will power
J. Salcedo
the calculator.

Meeting Summary

J. Salcedo described an appropriate
operational statistical process for the
project. The statistical methods identified
were influenced by the clinical evidence.

Meeting Outcome

Reflective Summarization

This meeting was similar to the one on 6/8. Internal communication between the
Agreed upon the constraints and
collaborators remains strong, and our respected expertise easily translates into the project.
benchmarks that will be utilized to
Just as I have taken time to brush up on statistics - Jonathan has taken the time to become
power the calculator
acquainted with the clinical literature which supports the intervention (PDHM).

We have the operational framework for the cost-calculator, at this point Jonathan and I
engaged in a implementation-focused evaluation. The central focus of this meeting as to ask
ourselves if our constructed framework was appropriate.

Finalize the selection
of the clinical data that
Presented an updated literature search.
C. Schmaltz &
will be used to
Made the final selection of the clinical data
J. Salcedo
support the
that will be used to power the calculator.
intervention.

Data reported by O'Connor et al.
(2016) RCT will serve to power
the effectiveness of the
intervention.

Jonathan and I are agreement that the O'Connor data is appropriate for our calculator. I am
now satisfied that our calculator utilizes appropriate data for the intervention construct
(exposure to PDHM). The process of working in a collegial interdisciplinary project has
granted me opportunities to approach the reimbursement issue from a fiscal vantage that I
otherwise likely would not have explored in my DNP program.

Teleconference

Search the Agency for
Healthcare Research
C. Schmaltz &
and Quality Healthcare
J. Salcedo
Cost and Utilization
Project Database.

Website down - Unable to meet
the meeting's objective.

This is frustrating; however, our team dynamic fosters project adjustments in response to
an unforeseen circumstance. Perhaps during the initial stages of the project, we could have
explored various contingency plans if we were unable to obtain data dependent upon
corporations and government entities.

Teleconference

Georgia specific data still unavailable.
Search the Agency for
Utilized HCUPnet.net; however, Georgia
Healthcare Research
does not report the necessary data for the
C. Schmaltz &
and Quality Healthcare
project, unlike other states in the Southeast
J. Salcedo
Cost and Utilization
Region. Made plans to change the costProject Database.
calculator from 'state specific' to 'region
specific.'

Website down - Unable to meet
the meeting's objective. Primary
collaborators will reach out to
senior team members to discuss
contingency plans.

The project may need to be reformatted. If the project needs to be reformatted, we will need
to ensure that J. Salcedo's expertise is properly utilized.

Phone Call

Evaluate GA specific
data provided from the C. Schmaltz &
Department of
J. Salcedo
Community Health.

Deemed data provided by GA is
appropriate to meet the project's
objective; J. Salcedo will include
the GA data in the calculator.

I continue to move out of my comfort level as I expand upon my understanding of costeffectiveness models. I continue to offer input as we integrate the data into our statistical
analysis.

Phone Call

Investigate the
differences between
GA specific data
Ran data from both sources, and decided
obtained from the
C. Schmaltz &
that the cost calculator was more sensitive
Department of
J. Salcedo
related to the utilization of the state data.
Community Health vs.
Region Specific
HCUPnet.gov.

Recommit to a calculator that is
state sensitive.

The prior months could have derailed the entire project; however, the project's objective and
evidence-based framework allowed primary collaborators to remain focused yet flexible.

12/5/18

9/26/18

9/4/18

C. Schmaltz will request state
specific Cost Data

10/24/18

Meeting Type
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11/30/18

Date

8/4/18

Medicaid Reimbursement

Phone Call

Review the current
state of the project.

C. Schmaltz &
J. Salcedo

Reviewed and analyzed the project's
framework.

State specific cost data had not yet been
provided by Georgia's DPH; explored
HCUPnet.gov as an alternative source.

Analyzed the data provided by the GA
DCH.

Medicaid Reimbursement

Meeting Objective

Team Members
Present

Meeting Summary

Primary collaborators evaluated the
preliminary version of the cost calculator,
Determine if the cost
leading to adjustments in the cost
C. Schmaltz &
calculator is meeting
calculator interface. Collaborators then
J. Salcedo
the project's objective.
reviewed results of the statistical
evaluation (single and multivariable
analysis).

Meeting Outcome

Reflective Summarization

Project is currently on target.

The project is on target. Both team members are able to articulate the importance of the variables outside
of their silo.

Teleconference

Teleconference

Present a working
C. Schmaltz, J.
calculator to a senior
Salcedo, & L.
member of the team
Summers
for feedback.

Primary collaborators presented an
operating version of the cost calculator.

L. Summers suggested to change the
VLBW from an absolute number to a
percentage of births.

Getting outside feedback proved helpful. Initial concerns of silo thinking/unintended miscommunication
subsided early during the working relationship. Outside feedback provided reassurance that Jonathan and
I produced something meaningful. I was becoming concerned that Jonathan and I had somehow merged
silos and formed gunk; however, feedback from L. Summers was reassuring.

Teleconference

C. Schmaltz, J.
Present a working
Salcedo, & S.
calculator to a neonatal
Staebler
policy expert for
(neonatal
feedback.
policy expert)

Primary collaborators presented an
operating version of the cost calculator.

S. Staebler recommended adjusting the
feeding plan; otherwise, received
positive feedback and look forward to
implementing the tool.

Reassuring; presenting the tool with J. Salcedo has increased my confidence that I will be able to
present the calculator alone and answer questions concerning the statistical analysis.

Phone Call

Implement the feeding
C. Schmaltz &
plan into the
J. Salcedo
calculator.

Adjustment of inputs rely on the feeding
plan.

The initial feeding plan over-estimated
intervention costs. By utilizing a
feeding plan consistent with clinical
practice, the tool continues to
demonstrate Medicaid cost savings.

This was a piece of information required for the calculator. The feeding plan allowed the calculator to be
reflective of clinical feeding practices. The collaboration produced an evidence-based tool to be utilized
while advocating for PDHM reimbursement policies. The interdisciplinary project created a tool built
upon clinical evidence and validated with statistical analysis. I am really proud of our accomplishments.

1/11/19

12/20/18

12/10/18

Meeting Type

12/19/18

Date
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